<?xml version='1.0' encoding='utf-8'?>
<graphml xmlns="http://graphml.graphdrawing.org/xmlns" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://graphml.graphdrawing.org/xmlns http://graphml.graphdrawing.org/xmlns/1.0/graphml.xsd"><key id="d4" for="edge" attr.name="width" attr.type="double"/>
<key id="d3" for="edge" attr.name="title" attr.type="string"/>
<key id="d2" for="node" attr.name="size" attr.type="long"/>
<key id="d1" for="node" attr.name="color" attr.type="string"/>
<key id="d0" for="node" attr.name="group" attr.type="long"/>
<graph edgedefault="undirected"><node id="abx">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">17</data>
</node>
<node id="alpha-synuclein">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">4</data>
</node>
<node id="alpha-synuclein autophagy-lysosome degradation pathways">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">1</data>
</node>
<node id="ambroxol (abx)">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">15</data>
</node>
<node id="aneed">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">3</data>
</node>
<node id="aneed study">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="antibiotics (abx)">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">25</data>
</node>
<node id="antiparkinsonian drugs">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">2</data>
</node>
<node id="chaperone-mediated autophagy (cma)">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">3</data>
</node>
<node id="clinical outcome measures">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="degradation pathways">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">1</data>
</node>
<node id="dementia medications">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">2</data>
</node>
<node id="dementia with lewy bodies">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">4</data>
</node>
<node id="dementia with lewy bodies (dlb)">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">7</data>
</node>
<node id="digital cerebrospinal fluid (csf) biomarkers">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="double-blind">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="gba gene mutation">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">27</data>
</node>
<node id="gcase activity">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">20</data>
</node>
<node id="gcase dysfunction">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">2</data>
</node>
<node id="gcase enzyme activity">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">8</data>
</node>
<node id="gcase enzyme levels">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">1</data>
</node>
<node id="genome-wide association study (gwas)">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="glucocerebrosidase">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">14</data>
</node>
<node id="human cells">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">1</data>
</node>
<node id="in vivo experiments">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">2</data>
</node>
<node id="inclusion criteria">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="mckeith criteria">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="mild cognitive impairment due to dlb (mci-dlb)">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="parallel group design">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="parkinson's disease (pd)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">30</data>
</node>
<node id="patients">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">62</data>
</node>
<node id="placebo-controlled">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">2</data>
</node>
<node id="population studies">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="preclinical trials">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">1</data>
</node>
<node id="randomized">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="rationale for treatment">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">1</data>
</node>
<node id="toxic alpha-synuclein (as) species">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">4</data>
</node>
<node id="cerebrospinal fluid (csf)">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">4</data>
</node>
<node id="effects">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">2</data>
</node>
<node id="glucocerebrosidase (gcase) activity">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">9</data>
</node>
<node id="lysosomal alpha-synuclein clearance">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">1</data>
</node>
<node id="mechanism of action">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">2</data>
</node>
<node id="synucleinopathies">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">3</data>
</node>
<node id="treatment rationale">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">1</data>
</node>
<node id="pathological deposition">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="modifying drug">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">1</data>
</node>
<node id="safety">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">5</data>
</node>
<node id="tolerability">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">2</data>
</node>
<node id="clinical trial">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">48</data>
</node>
<node id="efficacy profile">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="patients with dlb">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="safety profile">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">5</data>
</node>
<node id="tolerability profile">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="study participants">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">8</data>
</node>
<node id="dosage">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">9</data>
</node>
<node id="pathological alpha-synuclein (as) depositions">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">2</data>
</node>
<node id="treatment efficacy">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">6</data>
</node>
<node id="disease-modifying pharmacological treatment">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="dementia">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">3</data>
</node>
<node id="diagnosis">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">6</data>
</node>
<node id="risk of developing pd">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="alpha-synuclein metabolism">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="risk of developing">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="1 year post-diagnosis">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="4 mm concentration">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">2</data>
</node>
<node id="5 mm concentration">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">2</data>
</node>
<node id="90 mg/day">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">2</data>
</node>
<node id="adjusted hazard ratio">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">2</data>
</node>
<node id="ambroxol">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">98</data>
</node>
<node id="ambroxol treatment">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">5</data>
</node>
<node id="ambroxol users">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">5</data>
</node>
<node id="animal models of pd">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="anonymized data">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">4</data>
</node>
<node id="approved dose range">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="charlson comorbidity index">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">1</data>
</node>
<node id="chronic liver disease (cld) patients">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">7</data>
</node>
<node id="chronic lung disease (cld)">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">3</data>
</node>
<node id="chronic respiratory disease">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">2</data>
</node>
<node id="clinical practice">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">2</data>
</node>
<node id="comorbidities">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">3</data>
</node>
<node id="confidence interval">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">1</data>
</node>
<node id="cumulative defined daily doses">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">2</data>
</node>
<node id="cumulative incidence of parkinson's disease (pd)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">2</data>
</node>
<node id="data">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">4</data>
</node>
<node id="declaration of helsinki">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">4</data>
</node>
<node id="demographics">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">2</data>
</node>
<node id="dose-incidence relationship">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">1</data>
</node>
<node id="enzymatic activity">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">4</data>
</node>
<node id="further research">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="gaucher disease">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">19</data>
</node>
<node id="gba cellular models">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="gba gene">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">6</data>
</node>
<node id="gcase enzyme">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">5</data>
</node>
<node id="glucocerebrosidase enzyme">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">5</data>
</node>
<node id="hallym university dongtan sacred hospital">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">1</data>
</node>
<node id="high doses">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="high-dose administration">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">2</data>
</node>
<node id="high-dose ambroxol">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">13</data>
</node>
<node id="idiopathic parkinson's disease brain">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">3</data>
</node>
<node id="incidence rate">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="informed consents">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">4</data>
</node>
<node id="institutional review board">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">4</data>
</node>
<node id="korea pharmaceutical information center">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="korean national health insurance database (nhid)">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="long-term administration">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">1</data>
</node>
<node id="medications">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">2</data>
</node>
<node id="nonhuman primates">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="parkinson's disease">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">33</data>
</node>
<node id="parkinson's disease (pd) brain">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">4</data>
</node>
<node id="parkinson's disease patients">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">2</data>
</node>
<node id="pathogenesis of parkinson's disease">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">4</data>
</node>
<node id="recommended dosage">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="research procedures">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">4</data>
</node>
<node id="research protocol">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">3</data>
</node>
<node id="research study">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">7</data>
</node>
<node id="risk">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">1</data>
</node>
<node id="risk factor">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">2</data>
</node>
<node id="risk factors">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">1</data>
</node>
<node id="risk of parkinson's disease (pd)">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">5</data>
</node>
<node id="sensitivity analyses">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">1</data>
</node>
<node id="standard dosage">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="study results">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">6</data>
</node>
<node id="transgenic mice">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="usual dosage">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="α-synuclein protein">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">4</data>
</node>
<node id="chronic lung disease (cld) diagnosis">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="alpha-synuclein levels">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">5</data>
</node>
<node id="disease-modifying agent">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">2</data>
</node>
<node id="dosing schedule">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="effectiveness">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="expectorant">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="human subjects">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">2</data>
</node>
<node id="nonusers">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">2</data>
</node>
<node id="pharmaceutical">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">10</data>
</node>
<node id="standard dose">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="therapeutic agent">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">4</data>
</node>
<node id="therapeutic application">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="treatment">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">9</data>
</node>
<node id="100 mg/day">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">1</data>
</node>
<node id="22.5 mg/day">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">1</data>
</node>
<node id="deidentified data">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">2</data>
</node>
<node id="ambroxol nonusers">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">1</data>
</node>
<node id="pd risk">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="threshold of &gt;15">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">1</data>
</node>
<node id="ethical guidelines">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">2</data>
</node>
<node id="regulatory standards">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">2</data>
</node>
<node id="clinical case studies">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="α-synuclein protein level">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">1</data>
</node>
<node id="pd progression">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">1</data>
</node>
<node id="prescriptions">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="higher dosage">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="findings">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">2</data>
</node>
<node id="parkinson's disease (pd) incidence">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="long-term high-dose administration">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">1</data>
</node>
<node id="accumulation">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="4.5 years">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">2</data>
</node>
<node id="antibiotic abx">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">2</data>
</node>
<node id="abx compound">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">7</data>
</node>
<node id="abx concentration">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">2</data>
</node>
<node id="abx hydrochloride">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">6</data>
</node>
<node id="abx treatment">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">14</data>
</node>
<node id="adverse events">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">12</data>
</node>
<node id="adverse reactions">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="antibiotic">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">2</data>
</node>
<node id="antibiotic treatment (abx)">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">9</data>
</node>
<node id="baseline">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">3</data>
</node>
<node id="baseline gcase activity (pre-ert)">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">2</data>
</node>
<node id="biochemical outcomes">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">2</data>
</node>
<node id="blood sample">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">5</data>
</node>
<node id="blood-brain barrier (bbb)">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">5</data>
</node>
<node id="central nervous system">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">3</data>
</node>
<node id="clinical outcomes">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">5</data>
</node>
<node id="clinical participants">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="clinically significant abnormal findings">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">2</data>
</node>
<node id="combined therapy">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">7</data>
</node>
<node id="dosage (27 mg/kg/day)">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">2</data>
</node>
<node id="dosage concentrations">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">3</data>
</node>
<node id="early administration">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="efficacy">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">5</data>
</node>
<node id="enzyme replacement therapy">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">6</data>
</node>
<node id="enzyme replacement therapy (ert)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">14</data>
</node>
<node id="gaucher disease (gd)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">19</data>
</node>
<node id="gcase mutant proteins">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">1</data>
</node>
<node id="glucocerebrosidase (gcase)">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">12</data>
</node>
<node id="glucocerebrosidase activity">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">3</data>
</node>
<node id="hematological manifestations">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">1</data>
</node>
<node id="high-dose antibiotics (abx)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">10</data>
</node>
<node id="high-dose antibiotics (abx) + enzyme replacement therapy (ert)">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">3</data>
</node>
<node id="improvement">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="laboratory data">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">2</data>
</node>
<node id="long-term safety">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">2</data>
</node>
<node id="long-term treatment">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">5</data>
</node>
<node id="lyso-gb1">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">4</data>
</node>
<node id="medical treatment">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="modified sandhoff scale test (msst) score">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">5</data>
</node>
<node id="nci common toxicity criteria v4">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">2</data>
</node>
<node id="neurocognitive function">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">2</data>
</node>
<node id="neurological gaucher disease (ngd) patients">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">3</data>
</node>
<node id="neurological manifestations">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">6</data>
</node>
<node id="neurological progression of niemann-pick disease">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">2</data>
</node>
<node id="neuronopathic gaucher disease">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">7</data>
</node>
<node id="niemann-pick disease type b (ngd)">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">3</data>
</node>
<node id="patients (pt1–4)">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="patients with gaucher disease">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">4</data>
</node>
<node id="peripheral leukocytes">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">3</data>
</node>
<node id="pharmacokinetic assessment">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="pharmacokinetic parameters">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="pharmacokinetics">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">3</data>
</node>
<node id="pharmacokinetics (pk)">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="pharmacological agent">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="primary endpoint">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="progression">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="residual gcase activity">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">3</data>
</node>
<node id="results">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">3</data>
</node>
<node id="safety assessment">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">5</data>
</node>
<node id="secondary endpoints">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">2</data>
</node>
<node id="skeletal manifestations">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">1</data>
</node>
<node id="study duration">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">8</data>
</node>
<node id="substrate reduction therapy">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">2</data>
</node>
<node id="treatment duration">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">7</data>
</node>
<node id="trough plasma concentration">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">5</data>
</node>
<node id="visceral manifestations">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">1</data>
</node>
<node id="cerebrospinal fluid concentration">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">1</data>
</node>
<node id="fibroblast cells">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">1</data>
</node>
<node id="plasma concentration">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">1</data>
</node>
<node id="1.5 mg/kg/day">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="27 mg/kg/day">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">5</data>
</node>
<node id="3 mg/kg/day">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="daily dosage">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="oral administration">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="dosage regimens">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">3</data>
</node>
<node id="increased dosage (27 mg/kg/day)">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="initial dosage (21 mg/kg/day)">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="documentation">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="severity">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">2</data>
</node>
<node id="concentrations">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">1</data>
</node>
<node id="glucocerebrosidase (gcase) chaperone">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">1</data>
</node>
<node id="mucolytic agent">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">3</data>
</node>
<node id="therapeutic benefit">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">1</data>
</node>
<node id="cerebrospinal fluid (csf) concentration">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="concentration">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="initial dose (1.5 mg/kg/day)">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="maximum dose (27 mg/kg/day)">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="seizure frequency">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">2</data>
</node>
<node id="tolerance">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="treatment duration (5 days)">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">2</data>
</node>
<node id="treatment effectiveness">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="treatment outcomes">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">2</data>
</node>
<node id="pharmacokinetic analysis">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">3</data>
</node>
<node id="central nervous system (cns) features">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">1</data>
</node>
<node id="progressive neurological manifestations">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="ert">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">1</data>
</node>
<node id="systemic manifestations">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">5</data>
</node>
<node id="neurological symptoms">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">4</data>
</node>
<node id="lysosomal storage disorder">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="p.arg296gln">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="p.asn227ser">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="p.leu483pro">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="p.phe252ile">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="p.val211phefs">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="achieved activity (13.7±4.4%)">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="increased activity">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="mean normal activity">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="gcase">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">9</data>
</node>
<node id="residual enzymatic activity">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="in vitro and in vivo data">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">1</data>
</node>
<node id="biochemical assessments">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="neurocognitive assessments">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="hematological profile">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="biomarker">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="biomarker for gaucher disease (gd)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="progression of gaucher disease (gd)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="12.3±6">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="2.5 years of treatment">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="4.5 years of treatment">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="grading">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="long-term clinical safety">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="clinical improvement">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="ngd">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">1</data>
</node>
<node id="therapeutic intervention">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">19</data>
</node>
<node id="patient population">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">3</data>
</node>
<node id="clinical treatment">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="lyso-gb1 normalization">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="niemann-pick disease type c">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="number of subjects (4)">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="final phase (last 2 years)">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="initial phase (2.5 years)">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="in vitro studies">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">3</data>
</node>
<node id="srt">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">1</data>
</node>
<node id="4–14 years">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">1</data>
</node>
<node id="10 µmol/l">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="2.3–5.7 µmol/l">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="concentration range (3.2–8.8 µmol/l)">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="150 mg/day">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="2009">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="28-year-old female patient">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">1</data>
</node>
<node id="adverse events (aes)">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">13</data>
</node>
<node id="ambroxol hydrochloride">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">14</data>
</node>
<node id="biotech company">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">2</data>
</node>
<node id="british inds">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="carriers">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">3</data>
</node>
<node id="clinical registries">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="clinicaltrials.gov">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">3</data>
</node>
<node id="countries">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">4</data>
</node>
<node id="discontinuation of therapy">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="eight patients">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="enzyme replacement therapies (erts)">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">3</data>
</node>
<node id="exemption">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">1</data>
</node>
<node id="experimental drugs">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">3</data>
</node>
<node id="fatigue_level">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">2</data>
</node>
<node id="first 41 patients">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="gaucher disease type 1 (gd1)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">7</data>
</node>
<node id="gaucher disease type 2">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">2</data>
</node>
<node id="gaucher disease type 3 (gd3) patients">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">2</data>
</node>
<node id="gaucher disease-specific therapy">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">2</data>
</node>
<node id="gaucher unit">
  <data key="d0">23</data>
  <data key="d1">#6cdb57</data>
  <data key="d2">2</data>
</node>
<node id="gba-associated parkinson's disease (gba-pd)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">15</data>
</node>
<node id="gd2">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">2</data>
</node>
<node id="generic drug forms">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">2</data>
</node>
<node id="good responder">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="healthcare professionals">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">4</data>
</node>
<node id="healthcare providers">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">3</data>
</node>
<node id="identifier">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">2</data>
</node>
<node id="ii-reg">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">6</data>
</node>
<node id="in vivo studies">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="increased dosage">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="increased_level_physical_activity">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="index case">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">1</data>
</node>
<node id="individual cases">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="infants">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">1</data>
</node>
<node id="international registry">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">2</data>
</node>
<node id="investigator-initiated registry">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">3</data>
</node>
<node id="japanese inds">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="korean inds">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="limited ability to pay">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="median age">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">2</data>
</node>
<node id="monthly dosage">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="mutant gcase">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="mutant glucocerebrosidase">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">2</data>
</node>
<node id="myoclonic epilepsy">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">4</data>
</node>
<node id="neurodegenerative disease (ngd)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">2</data>
</node>
<node id="neurological_status">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">2</data>
</node>
<node id="neuronopathic gaucher disease (ngd)">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">8</data>
</node>
<node id="niemann-pick disease type c (ngd)">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">4</data>
</node>
<node id="off-label use">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">3</data>
</node>
<node id="over-the-counter (otc)">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="patient">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">7</data>
</node>
<node id="patient 14">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="patient cohorts">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">2</data>
</node>
<node id="patients worldwide">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="pharmaceutical companies">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">2</data>
</node>
<node id="pharmaceutical compound">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">10</data>
</node>
<node id="pharmaceutical industry">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">2</data>
</node>
<node id="phase 3 eliglustat engage trial">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">2</data>
</node>
<node id="phase ii regulatory study (ii-reg)">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">1</data>
</node>
<node id="physical_activity">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">2</data>
</node>
<node id="pilot study">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="placebo arm">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">1</data>
</node>
<node id="potential treatment">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">1</data>
</node>
<node id="preliminary efficacy data">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">2</data>
</node>
<node id="preliminary research findings">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">2</data>
</node>
<node id="profile of adverse events (aes)">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="protocol identifier">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">2</data>
</node>
<node id="real-world evidence">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">3</data>
</node>
<node id="real-world observational data">
  <data key="d0">23</data>
  <data key="d1">#6cdb57</data>
  <data key="d2">1</data>
</node>
<node id="reduced_level_fatigue">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="refractory myoclonic epilepsy">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="registry">
  <data key="d0">23</data>
  <data key="d1">#6cdb57</data>
  <data key="d2">3</data>
</node>
<node id="research and development">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">2</data>
</node>
<node id="research centers">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">3</data>
</node>
<node id="retrospective data">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">2</data>
</node>
<node id="safety and efficacy">
  <data key="d0">23</data>
  <data key="d1">#6cdb57</data>
  <data key="d2">3</data>
</node>
<node id="safety concerns">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="severe ataxia">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="small molecules">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">8</data>
</node>
<node id="spleen volumes">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">2</data>
</node>
<node id="srt (small molecule receptor therapy)">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">1</data>
</node>
<node id="therapeutics">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">5</data>
</node>
<node id="pharmacological chaperone">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">5</data>
</node>
<node id="allergic reaction">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">1</data>
</node>
<node id="cough">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">1</data>
</node>
<node id="disease progression">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">7</data>
</node>
<node id="dizziness">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">1</data>
</node>
<node id="efficacy data">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">1</data>
</node>
<node id="mild and transient effects">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">1</data>
</node>
<node id="mild proteinuria">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">1</data>
</node>
<node id="minor bowel discomfort">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">1</data>
</node>
<node id="availability">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="cost-effectiveness">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="disease-specific treatment">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">2</data>
</node>
<node id="dramatic improvement">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="global markets">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="high-dose">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="higher doses">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="in vitro testing">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="maximum dosage">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="medical prescription">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="neonatal gaucher disease (ngd)">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="non-gba carriers">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="off-label applications">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="over-the-counter (otc) dosage">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">3</data>
</node>
<node id="over-the-counter (otc) medication">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">4</data>
</node>
<node id="over-the-counter cough medication">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="therapeutic use">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="treating physician">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="cough suppressant">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="gba-parkinson disease">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="over-the-counter medication">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="demographic information">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">1</data>
</node>
<node id="response metrics">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="drug patent">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="multi-center, multi-national">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="drug development">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">2</data>
</node>
<node id="placebo-controlled design">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="early development phase">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="therapeutic modalities">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="13 different">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">1</data>
</node>
<node id="administration schedules">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="lysosomal storage diseases">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">1</data>
</node>
<node id="safe and effective">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="substrate reduction therapy (srt)">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">5</data>
</node>
<node id="success">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="reduced_level">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="medicine and industry">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="model of success">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="disease">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">2</data>
</node>
<node id="history of splenectomy">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="shaare zedek medical center">
  <data key="d0">23</data>
  <data key="d1">#6cdb57</data>
  <data key="d2">2</data>
</node>
<node id="affected patients">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">2</data>
</node>
<node id="disease-modifying therapies">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">4</data>
</node>
<node id="online purchase">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="developed nations">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="patient management">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">1</data>
</node>
<node id="seizure activity">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">1</data>
</node>
<node id="nct04388969">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">1</data>
</node>
<node id="efficacy monitoring">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="retrospective data collection">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="safety monitoring">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="type 2 gaucher disease (gd2)">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">2</data>
</node>
<node id="launch">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="registry ii-reg">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">1</data>
</node>
<node id="children">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="stable_or_improved">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="neuronopathic gd (ngd)">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">1</data>
</node>
<node id="high-dose ert">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="approved therapeutics">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">1</data>
</node>
<node id="specific treatment">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">2</data>
</node>
<node id="independent walking">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="treatment response">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="reported cases">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="25_patients">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="arabic and asian countries">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="gba mutation carriers">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="off-label ambroxol treatment">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="patient registry">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="potential therapeutic solutions">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="safety data">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">3</data>
</node>
<node id="splenectomized patients">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="interest">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">1</data>
</node>
<node id="increased_level">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="0097-20-szmc">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">1</data>
</node>
<node id="13">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">1</data>
</node>
<node id="unified case report form (crf)">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">1</data>
</node>
<node id="regulatory approval">
  <data key="d0">23</data>
  <data key="d1">#6cdb57</data>
  <data key="d2">1</data>
</node>
<node id="reported">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">1</data>
</node>
<node id="reduction">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="1-methyl-4-phenylpyridinium (mpp+)">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">9</data>
</node>
<node id="active compounds">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">2</data>
</node>
<node id="additive effects">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">4</data>
</node>
<node id="additive neuroprotective effect">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">1</data>
</node>
<node id="adenosine triphosphate (atp)">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">2</data>
</node>
<node id="α-synuclein triplication model">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">4</data>
</node>
<node id="anti-inflammatory properties">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">2</data>
</node>
<node id="biological pathways">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">4</data>
</node>
<node id="calcium excitotoxicity">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">2</data>
</node>
<node id="cell">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">2</data>
</node>
<node id="cell proliferation">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">4</data>
</node>
<node id="coenzyme">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="coenzyme q10">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">3</data>
</node>
<node id="combination medications">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">2</data>
</node>
<node id="combination therapy">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">6</data>
</node>
<node id="combinations of compounds">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="control cells">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">2</data>
</node>
<node id="creatine">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">4</data>
</node>
<node id="cytotoxicity">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">2</data>
</node>
<node id="dasatinib">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">8</data>
</node>
<node id="deferiprone">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">5</data>
</node>
<node id="diverse mechanisms of action">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">1</data>
</node>
<node id="dopaminergic induced pluripotent stem cells (ipscs)">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">3</data>
</node>
<node id="dopaminergic neurons">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">12</data>
</node>
<node id="dose-response experiment">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="drug candidate">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">2</data>
</node>
<node id="drug combinations">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">7</data>
</node>
<node id="drug repurposing">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">1</data>
</node>
<node id="energy depletion">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">2</data>
</node>
<node id="enhanced efficacy">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">1</data>
</node>
<node id="exenatide">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">6</data>
</node>
<node id="experimental conditions">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">4</data>
</node>
<node id="forty-four combinations">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">1</data>
</node>
<node id="free radical generation">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">2</data>
</node>
<node id="global research initiatives">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">2</data>
</node>
<node id="glycolytic pathway">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">2</data>
</node>
<node id="human cell line">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">2</data>
</node>
<node id="human dopaminergic ipscs">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">4</data>
</node>
<node id="human dopaminergic neurons">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">1</data>
</node>
<node id="human dopaminergic pluripotent stem cells">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">2</data>
</node>
<node id="human microglial cell line">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">3</data>
</node>
<node id="human microglia cells">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">2</data>
</node>
<node id="identified treatment combinations">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="idiopathic parkinson's disease">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">4</data>
</node>
<node id="in vitro models">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">3</data>
</node>
<node id="induced pluripotent stem cell (ipsc)-derived human dopaminergic neurons">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">4</data>
</node>
<node id="induced pluripotent stem cells (ipscs)">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">7</data>
</node>
<node id="initial screening">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">1</data>
</node>
<node id="ipd td16 cell line">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">4</data>
</node>
<node id="iron accumulation">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">2</data>
</node>
<node id="iron overload">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">1</data>
</node>
<node id="lipopolysaccharide (lps)">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">2</data>
</node>
<node id="microglial activation">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">2</data>
</node>
<node id="misfolded alpha-synuclein">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">2</data>
</node>
<node id="mitochondrial dysfunction">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">3</data>
</node>
<node id="mpp+ toxin">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">2</data>
</node>
<node id="neurite branching">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="neurite outgrowth">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">3</data>
</node>
<node id="neurodegeneration">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">8</data>
</node>
<node id="neurodegenerative disease">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">8</data>
</node>
<node id="neurofilament heavy chain (nfh)">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="neuroimmune responses">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">1</data>
</node>
<node id="neuroinflammation">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">6</data>
</node>
<node id="neuroprotection">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">3</data>
</node>
<node id="neuroprotective properties">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">2</data>
</node>
<node id="neuroprotective therapies">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">2</data>
</node>
<node id="nine pharmaceuticals">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">1</data>
</node>
<node id="parkinson's disease cell lines">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">1</data>
</node>
<node id="pathophysiological processes">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">5</data>
</node>
<node id="pba/exendin treatment">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">4</data>
</node>
<node id="personalized medicine">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">2</data>
</node>
<node id="pharmaceutical compounds">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">4</data>
</node>
<node id="pharmaceuticals">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">13</data>
</node>
<node id="phenylbutyrate">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="phosphoglycerate kinase 1">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">2</data>
</node>
<node id="potential solutions">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="preclinical models">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="q10">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">2</data>
</node>
<node id="reactive oxygen species (ros)">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">2</data>
</node>
<node id="research project">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="significant increase">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">2</data>
</node>
<node id="sodium phenylbutyrate">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">7</data>
</node>
<node id="sporadic parkinson's disease human ipsc line">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="substantia nigra">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">2</data>
</node>
<node id="synergistic efficacy">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">1</data>
</node>
<node id="tauroursodeoxycholic acid">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">5</data>
</node>
<node id="td16 parkinson's dopaminergic cell line">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">3</data>
</node>
<node id="terazosin">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">6</data>
</node>
<node id="testing">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">1</data>
</node>
<node id="testing procedure">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="tudca and exendin treatment">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">2</data>
</node>
<node id="tudca and pba treatment">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">2</data>
</node>
<node id="two-week differentiation period">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="various pathways">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="wild-type human dopaminergic induced pluripotent stem cell (ipsc) line">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">4</data>
</node>
<node id="α-synuclein triplication cell line">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">5</data>
</node>
<node id="neurotoxin">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="toxicity">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="combinations">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">2</data>
</node>
<node id="mucus hypersecretion">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="respiratory disorders">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="neurodegenerative processes">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">1</data>
</node>
<node id="mitochondrial function">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="energy buffering">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">2</data>
</node>
<node id="treated cells">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">1</data>
</node>
<node id="diverse patient population">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="targeted mechanism">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="atp production">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">2</data>
</node>
<node id="neuroprotective effect">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="pd patients">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">1</data>
</node>
<node id="pragmatic strategy">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">1</data>
</node>
<node id="natural supplement">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="cellular damage">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="5 nm concentration">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="c-abl inhibitor">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="chronic myeloid leukemia">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="combination testing">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="blood-brain barrier">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">3</data>
</node>
<node id="excess brain iron">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">2</data>
</node>
<node id="iron overload disorders">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">1</data>
</node>
<node id="mpp+ treatment">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="dopamine">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="neurotransmission">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="neurotransmitter">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="clinical potential">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">1</data>
</node>
<node id="evaluation">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">1</data>
</node>
<node id="mechanisms of action">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">4</data>
</node>
<node id="mechanistic targets">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">1</data>
</node>
<node id="clinical endpoint">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">3</data>
</node>
<node id="glp-1 (glucagon-like peptide-1)">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="microglial deactivation">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="type 2 diabetes mellitus">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="cellular atp production">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="neurotoxicity">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="neuroinflammation assessment">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">1</data>
</node>
<node id="patient-derived induced pluripotent stem cell line (ipsc)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="pd pathology diversity">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">1</data>
</node>
<node id="human">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="neurons">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="research">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="differentiation process">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">2</data>
</node>
<node id="metabolic pathways">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">2</data>
</node>
<node id="neuronal damage">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">2</data>
</node>
<node id="branching points">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="pharmacotherapy">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="pathways">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="inflammatory pathways">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">1</data>
</node>
<node id="affected population">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">1</data>
</node>
<node id="economic burden">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">1</data>
</node>
<node id="28-day duration">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">1</data>
</node>
<node id="in vivo models">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">1</data>
</node>
<node id="pathophysiological mechanisms">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">1</data>
</node>
<node id="oxidative stress pathways">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">1</data>
</node>
<node id="study limitations">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">1</data>
</node>
<node id="fda-approved drug">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">2</data>
</node>
<node id="glutamine levels">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="plasma ammonia levels">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="urea cycle disorders">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="alpha-synuclein aggregation">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">3</data>
</node>
<node id="endogenous bile acid">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="neuroprotective agent">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="benign prostatic hyperplasia">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="hypertension">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="α-synuclein accumulation">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">1</data>
</node>
<node id="90 days duration">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">2</data>
</node>
<node id="model organism">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="research model">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="60 days post-maturation">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">1</data>
</node>
<node id="tudca, exendin, and pba treatment">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">1</data>
</node>
<node id="cell line">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="5%–14%">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="abx compounds">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">2</data>
</node>
<node id="abx formulation">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">4</data>
</node>
<node id="active pharmaceutical ingredient">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="ambroxol chaperone">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">2</data>
</node>
<node id="antibiotics">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">5</data>
</node>
<node id="beta-glucocerebrosidase (gcase)">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">2</data>
</node>
<node id="biomarker assessments">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="brain mri imaging">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="cerebrospinal fluid (csf) neurodegeneration biomarkers">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">1</data>
</node>
<node id="changes in moca scale score">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">1</data>
</node>
<node id="clinical study">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">4</data>
</node>
<node id="cognitive assessments">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="cognitive impairment">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">5</data>
</node>
<node id="csf neurodegeneration biomarkers">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="double-blind study">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="gba-pd">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="glucosylceramide">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">5</data>
</node>
<node id="high-dose oral antibiotics">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">7</data>
</node>
<node id="investigational medicinal product (imp) treatment">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">1</data>
</node>
<node id="large cohort">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="material types">
  <data key="d0">26</data>
  <data key="d1">#57dbb7</data>
  <data key="d2">3</data>
</node>
<node id="materials science">
  <data key="d0">26</data>
  <data key="d1">#57dbb7</data>
  <data key="d2">11</data>
</node>
<node id="mild cognitive impairment (mci)">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">1</data>
</node>
<node id="moca scale score">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">2</data>
</node>
<node id="montreal cognitive assessment (moca) score">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">1</data>
</node>
<node id="motor evaluations">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="motor symptoms">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">3</data>
</node>
<node id="multicenter clinical trial">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">1</data>
</node>
<node id="multicenter phase iii">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">3</data>
</node>
<node id="neuroimaging biomarkers">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">1</data>
</node>
<node id="non-motor symptoms">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">3</data>
</node>
<node id="outcomes">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">2</data>
</node>
<node id="parkinson's disease dementia (pdd)">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">3</data>
</node>
<node id="patient compliance">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="patients with parkinson's disease (pd)">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">4</data>
</node>
<node id="pilot studies">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="placebo formulation">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="placebo-controlled study">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="primary objective">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">1</data>
</node>
<node id="primary outcome">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">2</data>
</node>
<node id="psychiatric assessments">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="randomized study">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="registration identifiers">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">3</data>
</node>
<node id="repeated-measures analysis of variance (anova)">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">1</data>
</node>
<node id="symptom progression">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">2</data>
</node>
<node id="tolerability assessments">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="validated assessment scales">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">2</data>
</node>
<node id="motor disabilities">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">1</data>
</node>
<node id="nonmotor disabilities">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">1</data>
</node>
<node id="neurodegeneration progression">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">1</data>
</node>
<node id="standard treatment dose">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="tablet count">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="clinical manifestations">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">2</data>
</node>
<node id="efficacy assessment">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="glucocerebrosidase (gcase) function">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">2</data>
</node>
<node id="bromhexine">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">1</data>
</node>
<node id="central nervous system (cns)">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">1</data>
</node>
<node id="gcase activity levels">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">1</data>
</node>
<node id="cognitive dysfunction">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">3</data>
</node>
<node id="quality of life">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="subclinical neuroprotective effects">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">2</data>
</node>
<node id="clinical efficacy">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">3</data>
</node>
<node id="good clinical practice">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">1</data>
</node>
<node id="study protocols">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">1</data>
</node>
<node id="evaluation process">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="motor function">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="multicenter">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="secondary outcomes">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">5</data>
</node>
<node id="primary outcome measures">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">3</data>
</node>
<node id="clinical subtypes">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="parkinson's disease risk">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="β-glucocerebrosidase enzyme">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="genetic risk factor">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="mutation carriers">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="mild mutations">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">2</data>
</node>
<node id="severe mutations">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">2</data>
</node>
<node id="age of onset">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="akinetic-rigid phenotype">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="dyskinesias">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="levodopa treatment">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="motor fluctuations">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="dementia risk">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="non-carrier individuals">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="survival rate">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="neurodegeneration biomarkers">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">2</data>
</node>
<node id="lysosomal enzyme">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="endoplasmic reticulum">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">2</data>
</node>
<node id="lysosome">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="protein levels">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">2</data>
</node>
<node id="ceramide">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="glucose">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="outcome measurements">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">1</data>
</node>
<node id="ceramics">
  <data key="d0">26</data>
  <data key="d1">#57dbb7</data>
  <data key="d2">2</data>
</node>
<node id="metals">
  <data key="d0">26</data>
  <data key="d1">#57dbb7</data>
  <data key="d2">1</data>
</node>
<node id="polymers">
  <data key="d0">26</data>
  <data key="d1">#57dbb7</data>
  <data key="d2">2</data>
</node>
<node id="biomaterials">
  <data key="d0">26</data>
  <data key="d1">#57dbb7</data>
  <data key="d2">1</data>
</node>
<node id="composite materials">
  <data key="d0">26</data>
  <data key="d1">#57dbb7</data>
  <data key="d2">1</data>
</node>
<node id="electronic materials">
  <data key="d0">26</data>
  <data key="d1">#57dbb7</data>
  <data key="d2">1</data>
</node>
<node id="metallurgy">
  <data key="d0">26</data>
  <data key="d1">#57dbb7</data>
  <data key="d2">1</data>
</node>
<node id="nanomaterials">
  <data key="d0">26</data>
  <data key="d1">#57dbb7</data>
  <data key="d2">1</data>
</node>
<node id="research initiative">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="positive results">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="phase ii trials">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="self-administers">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="abx 1.2 g/day dosage">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="global population">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="eudract 2021-004565-13">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="nct05287503">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="24 months">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="26 weeks">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="evidence">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">1</data>
</node>
<node id="peer-reviewed journals">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">1</data>
</node>
<node id="scientific conferences">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">1</data>
</node>
<node id="trial extension">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="symptomatic treatments">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="aggregation">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">1</data>
</node>
<node id="1 million individuals">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">2</data>
</node>
<node id="10.4%">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">3</data>
</node>
<node id="10.4% positive rate">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="12,580 patients">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="neuronopathic gd">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">3</data>
</node>
<node id="alleles">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="allosteric activator">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">2</data>
</node>
<node id="at-risk individuals">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="ataxia">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="awareness">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">2</data>
</node>
<node id="boehringer-ingelheim">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">1</data>
</node>
<node id="cell death">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">2</data>
</node>
<node id="clinical development">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">2</data>
</node>
<node id="comprehensive review">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">1</data>
</node>
<node id="current clinical trials">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="daily dose">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">2</data>
</node>
<node id="delivery">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="drug library">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">2</data>
</node>
<node id="early intervention">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">2</data>
</node>
<node id="early onset">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="endogenous mutant enzyme">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="enzyme misfolding">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="exogenous wildtype enzyme">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="gain of function mutation">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">2</data>
</node>
<node id="gba1 carriers">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">3</data>
</node>
<node id="gba1 d409v knock-out mouse model">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="gba1 gene">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">9</data>
</node>
<node id="gba1 mutation">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">2</data>
</node>
<node id="gba1 variant">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">4</data>
</node>
<node id="gba1-related parkinson's disease">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">28</data>
</node>
<node id="gba1-pd">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="genetic mutations">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">4</data>
</node>
<node id="genetic testing">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">9</data>
</node>
<node id="genetic variants">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">2</data>
</node>
<node id="glucocerebroside_substrate">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">2</data>
</node>
<node id="haploinsufficiency hypothesis">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="healthy volunteers">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">2</data>
</node>
<node id="homeostasis">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">2</data>
</node>
<node id="hypokinetic movement disorder">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">3</data>
</node>
<node id="idiopathic parkinson's disease (idiopathic pd)">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="increased awareness">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="investigator-initiated drug registry">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="low awareness">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="low-intensity focused ultrasound (lifu)">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">2</data>
</node>
<node id="macrophage_cells">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="magnetic resonance imaging (mri)">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">1</data>
</node>
<node id="management of early parkinson’s disease">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="medical community">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="medical understanding">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="meta-analysis">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="metabolic deficiencies">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="misfolded proteins">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">2</data>
</node>
<node id="movement disorders society">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">2</data>
</node>
<node id="movement disorders specialists">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="multinational multicenter study">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="neurologists">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">3</data>
</node>
<node id="new england journal of medicine">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="newly diagnosed patients">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">1</data>
</node>
<node id="novel pharmacological agents">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">2</data>
</node>
<node id="odds ratio">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">2</data>
</node>
<node id="official monitoring">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">1</data>
</node>
<node id="ongoing clinical trials">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">1</data>
</node>
<node id="parkinson's disease population">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">2</data>
</node>
<node id="pharmacological chaperones">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">4</data>
</node>
<node id="pharmacological chaperones (pcs)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">2</data>
</node>
<node id="pharmacological compound (pc)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">2</data>
</node>
<node id="phase 1–3 trials">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">1</data>
</node>
<node id="prodromal stages of parkinson's disease">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">3</data>
</node>
<node id="protein misfolding">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">7</data>
</node>
<node id="rare disease classification">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">4</data>
</node>
<node id="recombinant glucocerebrosidase">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">2</data>
</node>
<node id="reduction therapy">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">4</data>
</node>
<node id="report">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="reversibility">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="ropad study">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="safety trial">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="sanofi">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="scientific understanding">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="sidransky syndrome">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">16</data>
</node>
<node id="stress response mechanism">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">2</data>
</node>
<node id="survival duration">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="targeted therapies">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="targeted treatments">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="therapeutic strategies">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">2</data>
</node>
<node id="thermal denaturation assay">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="time to market">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="total population">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">2</data>
</node>
<node id="toxicology assessment">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="unfolded protein response">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="united states">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">4</data>
</node>
<node id="venglustat">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">6</data>
</node>
<node id="venglustat_treatment">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">2</data>
</node>
<node id="wild-type glucocerebrosidase">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">2</data>
</node>
<node id="cns_complications">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">2</data>
</node>
<node id="mutant enzyme">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">2</data>
</node>
<node id="australia">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="gaucher disease type 1 (gba1-pd)">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="glucocerebrosidase-specific pharmacological chaperone">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="international trust">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="mean dosage">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="non-gba1-related parkinson's disease">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="repurposed pharmaceutical">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="therapeutic effectiveness">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="therapeutic indications">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="early stage">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="study methodologies">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="active studies">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">1</data>
</node>
<node id="milligrams (mg)">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="enzyme">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">2</data>
</node>
<node id="substantia nigra region">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">1</data>
</node>
<node id="commercially approved drugs">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="prodromal stage">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="acceptance">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="rare genetic disorder">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="gba1-parkinson's disease (gba1-pd)">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="mutation">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">2</data>
</node>
<node id="earlier age of onset">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="established textbook knowledge">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="higher likelihood of developing dementia">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="more severe clinical course">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="symptoms of parkinson's disease">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="treatment of parkinson's disease">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="genetic etiology of parkinson's disease">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="rare diseases">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">2</data>
</node>
<node id="post-mortem brain analysis">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="metabolic_aspects_of_gaucher_disease">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="cerebral tissue">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="exogenous cerebrospinal fluid (csf)">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="protein folding defects">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">2</data>
</node>
<node id="protein stability issues">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">2</data>
</node>
<node id="lectures">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">2</data>
</node>
<node id="endoplasmic reticulum (er)">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="wild-type enzyme">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="brain tissue">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="enzyme activity">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="liver tissue">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="lysosomal_compartments">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">2</data>
</node>
<node id="substrate">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">2</data>
</node>
<node id="unproven approach">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">1</data>
</node>
<node id="mitigation">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">1</data>
</node>
<node id="severity level">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="international congress">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="common">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="5.43">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="neurological disorder">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">1</data>
</node>
<node id="debilitating condition">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="variant form">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="best interest">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="early management">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">1</data>
</node>
<node id="inflammation">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">1</data>
</node>
<node id="mutant alleles">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">1</data>
</node>
<node id="disease modification">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="diagnosis of parkinson's disease">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">1</data>
</node>
<node id="downstream effects">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="proteins">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="200,000 cases">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">1</data>
</node>
<node id="central nervous system delivery">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="phase i clinical trials">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">1</data>
</node>
<node id="phase ii clinical trials">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">1</data>
</node>
<node id="level of evidence">
  <data key="d0">23</data>
  <data key="d1">#6cdb57</data>
  <data key="d2">1</data>
</node>
<node id="care transformation">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="dementia prevalence">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="diagnostic strategies">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="disease onset">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="disease severity">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="consideration">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="treatment failure">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="academic discourse">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="drug development process">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="placebo">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="therapeutic potential">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="placebo_control">
  <data key="d0">20</data>
  <data key="d1">#db57c5</data>
  <data key="d2">1</data>
</node>
<node id="neurodegenerative pathology">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="bioactive compounds">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">2</data>
</node>
<node id="biological modulators">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">3</data>
</node>
<node id="cell-based assays">
  <data key="d0">27</data>
  <data key="d1">#57db7c</data>
  <data key="d2">4</data>
</node>
<node id="combinatorial matrix screening">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="compound identification">
  <data key="d0">27</data>
  <data key="d1">#57db7c</data>
  <data key="d2">2</data>
</node>
<node id="compound libraries">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">1</data>
</node>
<node id="compound ncgc326">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">4</data>
</node>
<node id="final hit compounds">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">2</data>
</node>
<node id="gaucher disease cell model">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">2</data>
</node>
<node id="gba1-knockout h4 cells">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="gcase enhancers">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">3</data>
</node>
<node id="gcase-l444p variant">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">5</data>
</node>
<node id="gsk-3 inhibitors">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">3</data>
</node>
<node id="hibit peptide reporter tag">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">2</data>
</node>
<node id="hibit-gcase-l444p assay">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">4</data>
</node>
<node id="hibit-tagged gcase">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">3</data>
</node>
<node id="high-throughput assays">
  <data key="d0">27</data>
  <data key="d1">#57db7c</data>
  <data key="d2">1</data>
</node>
<node id="high-throughput screening (hts)">
  <data key="d0">27</data>
  <data key="d1">#57db7c</data>
  <data key="d2">2</data>
</node>
<node id="immunofluorescence assay">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="lysosomal activity">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">2</data>
</node>
<node id="lysosomal translocation">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">2</data>
</node>
<node id="moderate expression">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="molecular identification">
  <data key="d0">27</data>
  <data key="d1">#57db7c</data>
  <data key="d2">2</data>
</node>
<node id="ncgc326">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">2</data>
</node>
<node id="novel chemical entities">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">1</data>
</node>
<node id="panobinostat">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="pharmacological agents">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">1</data>
</node>
<node id="pharmacological validation">
  <data key="d0">27</data>
  <data key="d1">#57db7c</data>
  <data key="d2">3</data>
</node>
<node id="physiologically relevant">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">1</data>
</node>
<node id="physiologically relevant assays">
  <data key="d0">27</data>
  <data key="d1">#57db7c</data>
  <data key="d2">1</data>
</node>
<node id="pladienolide b">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">4</data>
</node>
<node id="potent compounds">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">3</data>
</node>
<node id="proteasome inhibitors">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">3</data>
</node>
<node id="quantitative assays">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="screening process">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="small-molecule gcase enhancers">
  <data key="d0">27</data>
  <data key="d1">#57db7c</data>
  <data key="d2">1</data>
</node>
<node id="small-molecule stabilizers">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="therapeutic target">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="titration-based quantitative high-throughput screening">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="trans-isrib">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">3</data>
</node>
<node id="viability">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="cellular regulation">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="high-throughput screening">
  <data key="d0">27</data>
  <data key="d1">#57db7c</data>
  <data key="d2">1</data>
</node>
<node id="synergistic effects">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">1</data>
</node>
<node id="synergistic interactions">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">2</data>
</node>
<node id="glucosylsphingosine accumulation">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="proteostasis regulators">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">4</data>
</node>
<node id="epigenetic mechanisms">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">1</data>
</node>
<node id="monogenic disorder">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="related disorders">
  <data key="d0">17</data>
  <data key="d1">#db5f57</data>
  <data key="d2">1</data>
</node>
<node id="lead discovery">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">3</data>
</node>
<node id="biallelic loss-of-function mutations">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">1</data>
</node>
<node id="lysosomal localization">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">2</data>
</node>
<node id="trafficking obstruction">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="functional lysosomal activity">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="enzyme levels">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="therapeutic applications">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">2</data>
</node>
<node id="gcase variants">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="protein complexes (pcs)">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="protein residues (prs)">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">1</data>
</node>
<node id="endogenous gcase">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="pathogenic variant">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="conclusion">
  <data key="d0">26</data>
  <data key="d1">#57dbb7</data>
  <data key="d2">1</data>
</node>
<node id="material characterization">
  <data key="d0">26</data>
  <data key="d1">#57dbb7</data>
  <data key="d2">1</data>
</node>
<node id="materials engineering">
  <data key="d0">26</data>
  <data key="d1">#57dbb7</data>
  <data key="d2">1</data>
</node>
<node id="polymer science">
  <data key="d0">26</data>
  <data key="d1">#57dbb7</data>
  <data key="d2">1</data>
</node>
<node id="noninhibitory chaperones">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="medicinal chemistry optimization">
  <data key="d0">27</data>
  <data key="d1">#57db7c</data>
  <data key="d2">1</data>
</node>
<node id="screening methods">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">1</data>
</node>
<node id="development process">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<edge source="abx" target="cerebrospinal fluid (csf)">
  <data key="d3">penetrates into</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx" target="dementia with lewy bodies (dlb)">
  <data key="d3">is a modifying treatment in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx" target="effects">
  <data key="d3">show</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx" target="glucocerebrosidase (gcase) activity">
  <data key="d3">enhances effect on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx" target="lysosomal alpha-synuclein clearance">
  <data key="d3">enhances</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx" target="mechanism of action">
  <data key="d3">has unique mechanism on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx" target="synucleinopathies">
  <data key="d3">is tested in models of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx" target="toxic alpha-synuclein (as) species">
  <data key="d3">reduces concentration of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx" target="treatment rationale">
  <data key="d3">is established by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx" target="chaperone-mediated autophagy (cma)">
  <data key="d3">is a potential treatment for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx" target="preclinical trials">
  <data key="d3">show promising effects of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx" target="rationale for treatment">
  <data key="d3">is based on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx" target="cognitive impairment">
  <data key="d3">affects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx" target="disease-modifying agent">
  <data key="d3">is used as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx" target="motor disabilities">
  <data key="d3">affects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx" target="nonmotor disabilities">
  <data key="d3">affects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx" target="multicenter clinical trial">
  <data key="d3">tests</data>
  <data key="d4">1.0</data>
</edge>
<edge source="alpha-synuclein" target="dementia with lewy bodies">
  <data key="d3">is characterized by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="alpha-synuclein" target="pathological deposition">
  <data key="d3">causes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="alpha-synuclein" target="chaperone-mediated autophagy (cma)">
  <data key="d3">may reduce</data>
  <data key="d4">1.0</data>
</edge>
<edge source="alpha-synuclein" target="neurodegenerative pathology">
  <data key="d3">is not observed in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="alpha-synuclein autophagy-lysosome degradation pathways" target="gcase enzyme activity">
  <data key="d3">enhanced by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol (abx)" target="dementia with lewy bodies (dlb)">
  <data key="d3">is a modifying drug for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol (abx)" target="modifying drug">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol (abx)" target="patients">
  <data key="d3">is administered to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol (abx)" target="degradation pathways">
  <data key="d3">may affect</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol (abx)" target="gcase enzyme activity">
  <data key="d3">may increase</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol (abx)" target="gcase enzyme levels">
  <data key="d3">may increase</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol (abx)" target="blood-brain barrier (bbb)">
  <data key="d3">crosses</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol (abx)" target="concentrations">
  <data key="d3">used at</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol (abx)" target="glucocerebrosidase (gcase) chaperone">
  <data key="d3">identified as a pharmacological</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol (abx)" target="mucolytic agent">
  <data key="d3">is commonly used as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol (abx)" target="therapeutic benefit">
  <data key="d3">may represent a strategy for mediating</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol (abx)" target="gcase mutant proteins">
  <data key="d3">responsive to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol (abx)" target="bromhexine">
  <data key="d3">is a metabolite of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol (abx)" target="central nervous system (cns)">
  <data key="d3">easily enters</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol (abx)" target="safety profile">
  <data key="d3">has excellent</data>
  <data key="d4">1.0</data>
</edge>
<edge source="aneed" target="effects">
  <data key="d3">investigates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="aneed" target="safety">
  <data key="d3">investigates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="aneed" target="tolerability">
  <data key="d3">investigates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="aneed study" target="clinical trial">
  <data key="d3">is an</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="clinical trial">
  <data key="d3">is part of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="efficacy profile">
  <data key="d3">evaluates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="patients with dlb">
  <data key="d3">is tested on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="safety profile">
  <data key="d3">evaluates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="synucleinopathies">
  <data key="d3">is used for treating</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="tolerability profile">
  <data key="d3">evaluates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="patients">
  <data key="d3">are treated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="dosage">
  <data key="d3">administered at</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="gaucher disease">
  <data key="d3">is a treatment for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="27 mg/kg/day">
  <data key="d3">is the dosage of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="cerebrospinal fluid (csf) concentration">
  <data key="d3">has CSF concentration range</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="concentration">
  <data key="d3">has concentration range</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="pharmacokinetics">
  <data key="d3">related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="dosage (27 mg/kg/day)">
  <data key="d3">dosage of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="pharmacokinetic assessment">
  <data key="d3">involves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="pharmacokinetics (pk)">
  <data key="d3">analyzed by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="dosage concentrations">
  <data key="d3">has different</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="efficacy">
  <data key="d3">has uncertainties regarding</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="long-term safety">
  <data key="d3">has uncertainties regarding</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="neurological manifestations">
  <data key="d3">may help to arrest the progression of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="treatment duration">
  <data key="d3">is for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="treatment duration (5 days)">
  <data key="d3">is administered for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="treatment effectiveness">
  <data key="d3">is evaluated for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="treatment outcomes">
  <data key="d3">might achieve</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics (abx)" target="central nervous system">
  <data key="d3">is treated by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antiparkinsonian drugs" target="study participants">
  <data key="d3">are used by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antiparkinsonian drugs" target="dosage">
  <data key="d3">are prescribed in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="chaperone-mediated autophagy (cma)" target="pathological alpha-synuclein (as) depositions">
  <data key="d3">may reduce</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical outcome measures" target="treatment efficacy">
  <data key="d3">measures</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dementia medications" target="dosage">
  <data key="d3">are prescribed in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dementia medications" target="study participants">
  <data key="d3">are used by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dementia with lewy bodies" target="disease-modifying pharmacological treatment">
  <data key="d3">has no available</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dementia with lewy bodies" target="gba gene mutation">
  <data key="d3">increase risk of developing</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dementia with lewy bodies" target="cognitive dysfunction">
  <data key="d3">is associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dementia with lewy bodies (dlb)" target="dementia">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dementia with lewy bodies (dlb)" target="diagnosis">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dementia with lewy bodies (dlb)" target="gba gene mutation">
  <data key="d3">are more prevalent in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dementia with lewy bodies (dlb)" target="synucleinopathies">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dementia with lewy bodies (dlb)" target="patients">
  <data key="d3">have</data>
  <data key="d4">1.0</data>
</edge>
<edge source="digital cerebrospinal fluid (csf) biomarkers" target="treatment efficacy">
  <data key="d3">measures</data>
  <data key="d4">1.0</data>
</edge>
<edge source="double-blind" target="clinical trial">
  <data key="d3">is type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="parkinson's disease (pd)">
  <data key="d3">increase risk of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="risk of developing pd">
  <data key="d3">increases the</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="gcase dysfunction">
  <data key="d3">is caused by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="genome-wide association study (gwas)">
  <data key="d3">confirms correlation with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="enzymatic activity">
  <data key="d3">affects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="parkinson's disease (pd) brain">
  <data key="d3">is associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="pathogenesis of parkinson's disease">
  <data key="d3">suggests a link to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="idiopathic parkinson's disease brain">
  <data key="d3">may lack</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="parkinson's disease patients">
  <data key="d3">present in percentage of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="population studies">
  <data key="d3">demonstrate higher incidence of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="p.arg296gln">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="p.asn227ser">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="p.leu483pro">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="p.phe252ile">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="p.val211phefs">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="glucocerebrosidase (gcase)">
  <data key="d3">is affected by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="affected patients">
  <data key="d3">affects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="patients">
  <data key="d3">carrying</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="gaucher disease (gd)">
  <data key="d3">cause</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="genetic risk factor">
  <data key="d3">are a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="mutation carriers">
  <data key="d3">are associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="parkinson's disease dementia (pdd)">
  <data key="d3">increase risk of developing</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="patients with parkinson's disease (pd)">
  <data key="d3">carry</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="mild mutations">
  <data key="d3">classified as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene mutation" target="severe mutations">
  <data key="d3">classified as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="alpha-synuclein metabolism">
  <data key="d3">is associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="4 mm concentration">
  <data key="d3">may increase</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="5 mm concentration">
  <data key="d3">does not increase</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="ambroxol">
  <data key="d3">is affected by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="ambroxol treatment">
  <data key="d3">is increased by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="nonhuman primates">
  <data key="d3">shows increase in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="transgenic mice">
  <data key="d3">shows increase in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="achieved activity (13.7±4.4%)">
  <data key="d3">achieved after treatment</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="increased activity">
  <data key="d3">increases with dosage</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="mean normal activity">
  <data key="d3">expressed as percentage of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="peripheral leukocytes">
  <data key="d3">related to,related to</data>
  <data key="d4">2.0</data>
</edge>
<edge source="gcase activity" target="abx concentration">
  <data key="d3">associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="csf neurodegeneration biomarkers">
  <data key="d3">associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="mild mutations">
  <data key="d3">determines</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="neurodegeneration biomarkers">
  <data key="d3">is related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="severe mutations">
  <data key="d3">determines</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="motor symptoms">
  <data key="d3">associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="non-motor symptoms">
  <data key="d3">associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="symptom progression">
  <data key="d3">is associated with changes in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase activity" target="functional lysosomal activity">
  <data key="d3">is measured by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase dysfunction" target="glucocerebrosidase">
  <data key="d3">is related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase enzyme activity" target="in vivo experiments">
  <data key="d3">demonstrate effects on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase enzyme activity" target="α-synuclein protein level">
  <data key="d3">is negatively correlated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase enzyme activity" target="abx compound">
  <data key="d3">enhances</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase enzyme activity" target="blood sample">
  <data key="d3">analyzed in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase enzyme activity" target="cerebrospinal fluid (csf)">
  <data key="d3">analyzed in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase enzyme activity" target="therapeutic agent">
  <data key="d3">target</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase" target="gaucher disease">
  <data key="d3">is caused by deficiency of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase" target="gcase">
  <data key="d3">is also known as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase" target="allosteric activator">
  <data key="d3">activates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase" target="endoplasmic reticulum (er)">
  <data key="d3">is located within</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase" target="enzyme">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase" target="mutant enzyme">
  <data key="d3">can act on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase" target="parkinson's disease">
  <data key="d3">is influenced by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase" target="sidransky syndrome">
  <data key="d3">is associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase" target="wild-type enzyme">
  <data key="d3">can act on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase" target="wild-type glucocerebrosidase">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase" target="gba1 gene">
  <data key="d3">is encoded by gene</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase" target="small molecules">
  <data key="d3">are relevant to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase" target="small-molecule stabilizers">
  <data key="d3">are developed for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="human cells" target="glucocerebrosidase (gcase) activity">
  <data key="d3">is affected by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="in vivo experiments" target="study participants">
  <data key="d3">evidenced in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="inclusion criteria" target="study participants">
  <data key="d3">applies to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="mckeith criteria" target="diagnosis">
  <data key="d3">establishes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="mild cognitive impairment due to dlb (mci-dlb)" target="diagnosis">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parallel group design" target="clinical trial">
  <data key="d3">is a design type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="risk of developing">
  <data key="d3">is higher for carriers of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="ambroxol">
  <data key="d3">is used for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="comorbidities">
  <data key="d3">requires control for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="cumulative incidence of parkinson's disease (pd)">
  <data key="d3">is higher in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="further research">
  <data key="d3">need more investigation of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="incidence rate">
  <data key="d3">is a measure of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="carriers">
  <data key="d3">are associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="gaucher disease type 1 (gd1)">
  <data key="d3">diagnosed with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="combination medications">
  <data key="d3">used in combination for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="combination therapy">
  <data key="d3">is applicable to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="neurodegeneration">
  <data key="d3">leads to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="preclinical models">
  <data key="d3">of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="therapeutic intervention">
  <data key="d3">is a viable treatment for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="α-synuclein triplication model">
  <data key="d3">is related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="patient-derived induced pluripotent stem cell line (ipsc)">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="disease-modifying therapies">
  <data key="d3">are aimed at</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="neurodegenerative disease">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="parkinson's disease dementia (pdd)">
  <data key="d3">can progress to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="patient population">
  <data key="d3">is diagnosed in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="phase ii trials">
  <data key="d3">studies effects in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="12,580 patients">
  <data key="d3">is the sample size of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="early intervention">
  <data key="d3">may prevent or delay onset of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="early onset">
  <data key="d3">is characteristic of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="gaucher disease (gd)">
  <data key="d3">are conditions addressed by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="gba1 carriers">
  <data key="d3">are associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="debilitating condition">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="long-term treatment">
  <data key="d3">requires</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="variant form">
  <data key="d3">is a form of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd)" target="treatment">
  <data key="d3">requires a</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="chronic liver disease (cld) patients">
  <data key="d3">involves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="medications">
  <data key="d3">might take</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="adverse reactions">
  <data key="d3">experience</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="biochemical outcomes">
  <data key="d3">assessed after</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="blood sample">
  <data key="d3">provide</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="clinical outcomes">
  <data key="d3">are reported in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="dosage concentrations">
  <data key="d3">vary among</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="enzyme replacement therapy">
  <data key="d3">were treated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="neurological progression of niemann-pick disease">
  <data key="d3">is monitored in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="clinical treatment">
  <data key="d3">undergo</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="lyso-gb1 normalization">
  <data key="d3">experiences</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="niemann-pick disease type c">
  <data key="d3">were diagnosed with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="number of subjects (4)">
  <data key="d3">are</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="pharmacokinetic analysis">
  <data key="d3">are subjects of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="ambroxol">
  <data key="d3">use,are treated with</data>
  <data key="d4">2.0</data>
</edge>
<edge source="patients" target="clinical trial">
  <data key="d3">participated in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="countries">
  <data key="d3">are located in many</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="discontinuation of therapy">
  <data key="d3">is an action taken by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="enzyme replacement therapy (ert)">
  <data key="d3">are untreated with,are treated with,received</data>
  <data key="d4">3.0</data>
</edge>
<edge source="patients" target="fatigue_level">
  <data key="d3">reported in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="gaucher disease type 1 (gd1)">
  <data key="d3">affects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="gba-associated parkinson's disease (gba-pd)">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="healthcare providers">
  <data key="d3">collaborate with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="ii-reg">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="increased_level_physical_activity">
  <data key="d3">is an outcome for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="limited ability to pay">
  <data key="d3">affects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="median age">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="monthly dosage">
  <data key="d3">is administered to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="neurological_status">
  <data key="d3">reported in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="patient cohorts">
  <data key="d3">are part of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="25_patients">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="adverse events">
  <data key="d3">experience</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="arabic and asian countries">
  <data key="d3">live in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="gba mutation carriers">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="neuronopathic gaucher disease (ngd)">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="off-label ambroxol treatment">
  <data key="d3">are exposed to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="patient registry">
  <data key="d3">are part of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="physical_activity">
  <data key="d3">reported in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="potential therapeutic solutions">
  <data key="d3">seek</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="safety data">
  <data key="d3">provide</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="splenectomized patients">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="substrate reduction therapy (srt)">
  <data key="d3">are untreated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="treatment">
  <data key="d3">seek</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="treatment duration">
  <data key="d3">undergo</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="preliminary research findings">
  <data key="d3">may encourage</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="reduced_level_fatigue">
  <data key="d3">is an outcome for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="spleen volumes">
  <data key="d3">are measured in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="pathophysiological processes">
  <data key="d3">vary among</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="personalized medicine">
  <data key="d3">identifies based on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="gba-pd">
  <data key="d3">is a condition affecting</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="large cohort">
  <data key="d3">is a group of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="carriers">
  <data key="d3">are different from</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="daily dose">
  <data key="d3">receives</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="gaucher disease (gd)">
  <data key="d3">can have</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="investigator-initiated drug registry">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="off-label use">
  <data key="d3">may receive</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="report">
  <data key="d3">updates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients" target="therapeutic intervention">
  <data key="d3">provides for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="placebo-controlled" target="clinical trial">
  <data key="d3">is type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="placebo-controlled" target="therapeutic intervention">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="randomized" target="clinical trial">
  <data key="d3">is a characteristic of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="toxic alpha-synuclein (as) species" target="pathological alpha-synuclein (as) depositions">
  <data key="d3">is related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="toxic alpha-synuclein (as) species" target="glucocerebrosidase (gcase)">
  <data key="d3">increases non-soluble</data>
  <data key="d4">1.0</data>
</edge>
<edge source="toxic alpha-synuclein (as) species" target="aggregation">
  <data key="d3">promotes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cerebrospinal fluid (csf)" target="abx compounds">
  <data key="d3">analyzed in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cerebrospinal fluid (csf)" target="alpha-synuclein levels">
  <data key="d3">analyzed in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase (gcase) activity" target="ambroxol">
  <data key="d3">increases</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase (gcase) activity" target="alpha-synuclein levels">
  <data key="d3">are affected by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase (gcase) activity" target="antibiotic abx">
  <data key="d3">is affected by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase (gcase) activity" target="abx compound">
  <data key="d3">enhances</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase (gcase) activity" target="abx concentration">
  <data key="d3">correlates with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase (gcase) activity" target="in vitro and in vivo data">
  <data key="d3">show significant increases in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase (gcase) activity" target="therapeutic intervention">
  <data key="d3">should aim to correct</data>
  <data key="d4">1.0</data>
</edge>
<edge source="mechanism of action" target="pladienolide b">
  <data key="d3">has a novel</data>
  <data key="d4">1.0</data>
</edge>
<edge source="safety" target="enzyme replacement therapy (ert)">
  <data key="d3">was found to be</data>
  <data key="d4">1.0</data>
</edge>
<edge source="safety" target="high-dose antibiotics (abx)">
  <data key="d3">was found to be</data>
  <data key="d4">1.0</data>
</edge>
<edge source="safety" target="long-term treatment">
  <data key="d3">is evaluated for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="safety" target="high-dose oral antibiotics">
  <data key="d3">evaluates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="tolerability" target="high-dose oral antibiotics">
  <data key="d3">evaluates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="clinical participants">
  <data key="d3">completed</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="ambroxol">
  <data key="d3">are not needed for,evaluate,are ongoing for</data>
  <data key="d4">3.0</data>
</edge>
<edge source="clinical trial" target="biotech company">
  <data key="d3">unable to fund</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="drug development">
  <data key="d3">is part of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="placebo-controlled design">
  <data key="d3">may involve</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="ambroxol hydrochloride">
  <data key="d3">are lacking for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="early development phase">
  <data key="d3">are in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="therapeutic modalities">
  <data key="d3">test</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="pharmaceutical companies">
  <data key="d3">lead</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="diverse patient population">
  <data key="d3">involves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="targeted mechanism">
  <data key="d3">focuses on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="pharmaceutical compounds">
  <data key="d3">assessed in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="active pharmaceutical ingredient">
  <data key="d3">is used in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="clinical outcomes">
  <data key="d3">evaluates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="cognitive impairment">
  <data key="d3">measures evolution of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="evaluation process">
  <data key="d3">involves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="motor function">
  <data key="d3">compares with cognitive impairment</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="multicenter">
  <data key="d3">is a</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="multicenter phase iii">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="registration identifiers">
  <data key="d3">has</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="safety assessment">
  <data key="d3">assesses</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="study duration">
  <data key="d3">is a limitation of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="double-blind study">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="gba-associated parkinson's disease (gba-pd)">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="outcomes">
  <data key="d3">are evaluated in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="parkinson's disease">
  <data key="d3">is related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="placebo formulation">
  <data key="d3">is used in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="placebo-controlled study">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="randomized study">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="treatment efficacy">
  <data key="d3">did not show</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="multinational multicenter study">
  <data key="d3">is type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="venglustat">
  <data key="d3">is subject of,was tested in</data>
  <data key="d4">2.0</data>
</edge>
<edge source="clinical trial" target="high-dose ambroxol">
  <data key="d3">involves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="human subjects">
  <data key="d3">involve</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="gba1-related parkinson's disease">
  <data key="d3">conducts research on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="genetic testing">
  <data key="d3">requires</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="novel pharmacological agents">
  <data key="d3">involves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="study methodologies">
  <data key="d3">have different</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="gba1-pd">
  <data key="d3">are related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="haploinsufficiency hypothesis">
  <data key="d3">is basis for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical trial" target="healthy volunteers">
  <data key="d3">participate in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="safety profile" target="ambroxol">
  <data key="d3">has</data>
  <data key="d4">1.0</data>
</edge>
<edge source="safety profile" target="long-term high-dose administration">
  <data key="d3">needs to be confirmed for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="safety profile" target="high-dose antibiotics (abx)">
  <data key="d3">is generally associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="study participants" target="ambroxol">
  <data key="d3">took</data>
  <data key="d4">1.0</data>
</edge>
<edge source="study participants" target="neurocognitive function">
  <data key="d3">is assessed in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="study participants" target="in vitro studies">
  <data key="d3">evidenced in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="study participants" target="informed consents">
  <data key="d3">are enrolled after obtaining</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dosage" target="90 mg/day">
  <data key="d3">is an example of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dosage" target="ambroxol">
  <data key="d3">is measured in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dosage" target="clinical practice">
  <data key="d3">is permitted in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dosage" target="antibiotic treatment (abx)">
  <data key="d3">increased to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dosage" target="27 mg/kg/day">
  <data key="d3">escalated to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dosage" target="abx formulation">
  <data key="d3">allows gradual increase in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="treatment efficacy" target="high-dose administration">
  <data key="d3">may influence</data>
  <data key="d4">1.0</data>
</edge>
<edge source="treatment efficacy" target="early administration">
  <data key="d3">can enhance</data>
  <data key="d4">1.0</data>
</edge>
<edge source="treatment efficacy" target="high-dose antibiotics (abx)">
  <data key="d3">may improve</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dementia" target="ambroxol">
  <data key="d3">is used in treatment for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dementia" target="primary outcome measures">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="diagnosis" target="parkinson's disease dementia (pdd)">
  <data key="d3">occurs within 10 years of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="diagnosis" target="genetic testing">
  <data key="d3">is supported by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="diagnosis" target="gba1 gene">
  <data key="d3">is a prerequisite for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="1 year post-diagnosis" target="chronic lung disease (cld) diagnosis">
  <data key="d3">is the time frame after</data>
  <data key="d4">1.0</data>
</edge>
<edge source="4 mm concentration" target="ambroxol">
  <data key="d3">is at concentration</data>
  <data key="d4">1.0</data>
</edge>
<edge source="5 mm concentration" target="ambroxol">
  <data key="d3">is at concentration</data>
  <data key="d4">1.0</data>
</edge>
<edge source="90 mg/day" target="korea pharmaceutical information center">
  <data key="d3">provides dosage information for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adjusted hazard ratio" target="risk of parkinson's disease (pd)">
  <data key="d3">measures</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adjusted hazard ratio" target="confidence interval">
  <data key="d3">is associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="alpha-synuclein levels">
  <data key="d3">decreases</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="chronic lung disease (cld)">
  <data key="d3">is relevant to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="chronic lung disease (cld) diagnosis">
  <data key="d3">prescribed after</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="chronic respiratory disease">
  <data key="d3">is treated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="cumulative incidence of parkinson's disease (pd)">
  <data key="d3">is associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="disease-modifying agent">
  <data key="d3">is suggested to be a</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="dosing schedule">
  <data key="d3">is part of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="effectiveness">
  <data key="d3">is questioned</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="expectorant">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="high-dose administration">
  <data key="d3">is administered in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="human subjects">
  <data key="d3">is administered to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="nonusers">
  <data key="d3">compared to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="parkinson's disease">
  <data key="d3">is associated with risk of,is associated with</data>
  <data key="d4">2.0</data>
</edge>
<edge source="ambroxol" target="risk of parkinson's disease (pd)">
  <data key="d3">is associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="pharmaceutical">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="recommended dosage">
  <data key="d3">is prescribed at</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="standard dosage">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="standard dose">
  <data key="d3">does not produce</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="therapeutic agent">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="therapeutic application">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="treatment">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="approved dose range">
  <data key="d3">is the range within which Ambroxol is administered</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="chronic liver disease (cld) patients">
  <data key="d3">prescribed to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="clinical practice">
  <data key="d3">involves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="high doses">
  <data key="d3">is administered at</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="korean national health insurance database (nhid)">
  <data key="d3">is used to investigate</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="usual dosage">
  <data key="d3">is a standard measurement of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="neuronopathic gaucher disease">
  <data key="d3">is suggested as an augmentative pharmacological agent for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="pharmacological agent">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="150 mg/day">
  <data key="d3">is the dosage of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="adverse events (aes)">
  <data key="d3">is associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="availability">
  <data key="d3">is widely</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="cost-effectiveness">
  <data key="d3">is relatively</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="disease-specific treatment">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="dramatic improvement">
  <data key="d3">causes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="efficacy">
  <data key="d3">is related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="enzyme replacement therapy (ert)">
  <data key="d3">is studied for safety</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="gaucher disease (gd)">
  <data key="d3">is used for treating</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="gaucher disease type 1 (gd1)">
  <data key="d3">is used in treatment for,is used for treatment in</data>
  <data key="d4">2.0</data>
</edge>
<edge source="ambroxol" target="gba-associated parkinson's disease (gba-pd)">
  <data key="d3">is used for treatment in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="global markets">
  <data key="d3">faces barriers in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="high-dose">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="higher doses">
  <data key="d3">is administered in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="in vitro testing">
  <data key="d3">skips</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="maximum dosage">
  <data key="d3">has a specified</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="medical prescription">
  <data key="d3">does not require</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="neonatal gaucher disease (ngd)">
  <data key="d3">is used for treatment in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="niemann-pick disease type c (ngd)">
  <data key="d3">is treated by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="non-gba carriers">
  <data key="d3">is used in treatment for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="off-label applications">
  <data key="d3">considered for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="over-the-counter (otc) dosage">
  <data key="d3">is administered at</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="over-the-counter (otc) medication">
  <data key="d3">are related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="over-the-counter cough medication">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="pharmacological chaperone">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="therapeutic intervention">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="therapeutic use">
  <data key="d3">is associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="treating physician">
  <data key="d3">is prescribed by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="british inds">
  <data key="d3">tested for efficacy on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="clinical registries">
  <data key="d3">disallowed entry of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="eight patients">
  <data key="d3">stopped taking</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="good responder">
  <data key="d3">is treated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="japanese inds">
  <data key="d3">tested for efficacy on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="korean inds">
  <data key="d3">tested for efficacy on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="mutant gcase">
  <data key="d3">is targeted by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="myoclonic epilepsy">
  <data key="d3">is ameliorated by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="treatment duration">
  <data key="d3">is measured in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="mucolytic agent">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="mucus hypersecretion">
  <data key="d3">associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="pharmaceutical compound">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="respiratory disorders">
  <data key="d3">treats</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="australia">
  <data key="d3">tested in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="cough suppressant">
  <data key="d3">is classified as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="gaucher disease type 1 (gba1-pd)">
  <data key="d3">is used for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="gba1-related parkinson's disease">
  <data key="d3">is treated by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="glucocerebrosidase-specific pharmacological chaperone">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="international trust">
  <data key="d3">aims to upgrade</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="mean dosage">
  <data key="d3">has a</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="neurodegenerative disease (ngd)">
  <data key="d3">is used for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="non-gba1-related parkinson's disease">
  <data key="d3">hypothesized to be effective in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="repurposed pharmaceutical">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="therapeutic effectiveness">
  <data key="d3">may vary based on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="therapeutic indications">
  <data key="d3">is used for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="current clinical trials">
  <data key="d3">involve</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="idiopathic parkinson's disease (idiopathic pd)">
  <data key="d3">is treated by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="new england journal of medicine">
  <data key="d3">does not mention</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="pharmacological chaperones">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol" target="toxicology assessment">
  <data key="d3">is required for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol treatment" target="100 mg/day">
  <data key="d3">is effective at</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol treatment" target="22.5 mg/day">
  <data key="d3">is not effective at</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol treatment" target="adverse events (aes)">
  <data key="d3">are reported during</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol treatment" target="preliminary efficacy data">
  <data key="d3">is collected during</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol users" target="chronic liver disease (cld) patients">
  <data key="d3">are</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol users" target="cumulative defined daily doses">
  <data key="d3">are characterized by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol users" target="nonusers">
  <data key="d3">are compared in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol users" target="charlson comorbidity index">
  <data key="d3">is higher in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol users" target="risk of parkinson's disease (pd)">
  <data key="d3">is highest in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="animal models of pd" target="α-synuclein protein">
  <data key="d3">exhibit increased</data>
  <data key="d4">1.0</data>
</edge>
<edge source="anonymized data" target="deidentified data">
  <data key="d3">are types of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="anonymized data" target="data">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="anonymized data" target="demographic information">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="anonymized data" target="research study">
  <data key="d3">collected as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="chronic liver disease (cld) patients" target="study results">
  <data key="d3">might not apply to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="chronic liver disease (cld) patients" target="ambroxol nonusers">
  <data key="d3">are compared to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="chronic liver disease (cld) patients" target="demographics">
  <data key="d3">of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="chronic liver disease (cld) patients" target="risk of parkinson's disease (pd)">
  <data key="d3">is higher in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="chronic lung disease (cld)" target="parkinson's disease">
  <data key="d3">risk factor for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="chronic lung disease (cld)" target="korean national health insurance database (nhid)">
  <data key="d3">contains data on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="chronic respiratory disease" target="parkinson's disease">
  <data key="d3">can co-occur with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="comorbidities" target="pd risk">
  <data key="d3">increase</data>
  <data key="d4">1.0</data>
</edge>
<edge source="comorbidities" target="risk factor">
  <data key="d3">affects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cumulative defined daily doses" target="threshold of &gt;15">
  <data key="d3">is threshold for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="data" target="deidentified data">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="data" target="research procedures">
  <data key="d3">related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="data" target="informed consents">
  <data key="d3">given for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="declaration of helsinki" target="ethical guidelines">
  <data key="d3">provides</data>
  <data key="d4">1.0</data>
</edge>
<edge source="declaration of helsinki" target="regulatory standards">
  <data key="d3">provides</data>
  <data key="d4">1.0</data>
</edge>
<edge source="declaration of helsinki" target="research procedures">
  <data key="d3">performed in accordance with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="declaration of helsinki" target="clinical study">
  <data key="d3">is conducted according to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="demographics" target="gaucher disease">
  <data key="d3">is included in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dose-incidence relationship" target="risk of parkinson's disease (pd)">
  <data key="d3">shows correlation with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="enzymatic activity" target="pathogenesis of parkinson's disease">
  <data key="d3">is closely associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="enzymatic activity" target="parkinson's disease (pd) brain">
  <data key="d3">has decreased</data>
  <data key="d4">1.0</data>
</edge>
<edge source="enzymatic activity" target="glucocerebrosidase (gcase)">
  <data key="d3">is reduced in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease" target="clinical case studies">
  <data key="d3">is demonstrated in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease" target="gba gene">
  <data key="d3">mutates to cause</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease" target="high-dose ambroxol">
  <data key="d3">halts progression of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease" target="lysosomal storage disorder">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease" target="neurological manifestations">
  <data key="d3">are symptoms of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease" target="ambroxol hydrochloride">
  <data key="d3">is studied for use in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease" target="gaucher disease-specific therapy">
  <data key="d3">is associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease" target="enzyme misfolding">
  <data key="d3">is a primary driver of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease" target="acceptance">
  <data key="d3">delays</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease" target="parkinson's disease">
  <data key="d3">is linked to,is associated with</data>
  <data key="d4">2.0</data>
</edge>
<edge source="gaucher disease" target="rare genetic disorder">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease" target="metabolic deficiencies">
  <data key="d3">are seen in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease" target="monogenic disorder">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease" target="related disorders">
  <data key="d3">is related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease" target="glucocerebrosidase (gcase)">
  <data key="d3">is implicated in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease" target="mutation">
  <data key="d3">cause</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba cellular models" target="α-synuclein protein">
  <data key="d3">exhibit increased</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene" target="glucocerebrosidase enzyme">
  <data key="d3">encodes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene" target="parkinson's disease">
  <data key="d3">is genetic risk factor for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene" target="beta-glucocerebrosidase (gcase)">
  <data key="d3">encodes for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene" target="parkinson's disease risk">
  <data key="d3">is risk factor for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba gene" target="β-glucocerebrosidase enzyme">
  <data key="d3">encodes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase enzyme" target="α-synuclein protein">
  <data key="d3">negatively correlates with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase enzyme" target="glucocerebrosidase enzyme">
  <data key="d3">is also known as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase enzyme" target="lysosomal enzyme">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase enzyme" target="compound ncgc326">
  <data key="d3">is targeted by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase enzyme" target="small molecules">
  <data key="d3">target</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase enzyme" target="drug library">
  <data key="d3">screens</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase enzyme" target="thermal denaturation assay">
  <data key="d3">utilizes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase enzyme" target="glucocerebroside_substrate">
  <data key="d3">hydrolyzes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="hallym university dongtan sacred hospital" target="research protocol">
  <data key="d3">approved by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose ambroxol" target="pd progression">
  <data key="d3">modifies</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose ambroxol" target="long-term administration">
  <data key="d3">needs confirmation of safety for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose ambroxol" target="combined therapy">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose ambroxol" target="enzyme replacement therapy">
  <data key="d3">is combined with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose ambroxol" target="patient management">
  <data key="d3">is used for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose ambroxol" target="potential treatment">
  <data key="d3">is a designation for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose ambroxol" target="seizure activity">
  <data key="d3">improves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose ambroxol" target="off-label use">
  <data key="d3">is a method of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose ambroxol" target="mitigation">
  <data key="d3">aims to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose ambroxol" target="ongoing clinical trials">
  <data key="d3">involves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose ambroxol" target="pharmacological chaperones">
  <data key="d3">is an example of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="idiopathic parkinson's disease brain" target="parkinson's disease (pd) brain">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="idiopathic parkinson's disease brain" target="pathogenesis of parkinson's disease">
  <data key="d3">is relevant to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="informed consents" target="research protocol">
  <data key="d3">exempted from needing</data>
  <data key="d4">1.0</data>
</edge>
<edge source="informed consents" target="exemption">
  <data key="d3">received for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="institutional review board" target="research protocol">
  <data key="d3">reviews</data>
  <data key="d4">1.0</data>
</edge>
<edge source="institutional review board" target="protocol identifier">
  <data key="d3">has</data>
  <data key="d4">1.0</data>
</edge>
<edge source="institutional review board" target="clinical study">
  <data key="d3">is approved by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="institutional review board" target="research centers">
  <data key="d3">is part of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="medications" target="prescriptions">
  <data key="d3">are</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="risk">
  <data key="d3">is measured for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="risk factors">
  <data key="d3">include</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="1-methyl-4-phenylpyridinium (mpp+)">
  <data key="d3">is associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="disease-modifying therapies">
  <data key="d3">target</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="human dopaminergic neurons">
  <data key="d3">are relevant to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="in vitro models">
  <data key="d3">used for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="neurodegeneration">
  <data key="d3">is a process in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="neuroprotective therapies">
  <data key="d3">target</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="affected population">
  <data key="d3">affects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="disease progression">
  <data key="d3">slowed by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="economic burden">
  <data key="d3">costs annually</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="neurodegenerative disease">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="pharmaceuticals">
  <data key="d3">treated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="therapeutic intervention">
  <data key="d3">is for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="1 million individuals">
  <data key="d3">affects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="comprehensive review">
  <data key="d3">published on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="gba1 mutation">
  <data key="d3">is related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="newly diagnosed patients">
  <data key="d3">are,are</data>
  <data key="d4">2.0</data>
</edge>
<edge source="parkinson's disease" target="neurological disorder">
  <data key="d3">is a type of,is a subtype of</data>
  <data key="d4">2.0</data>
</edge>
<edge source="parkinson's disease" target="rare disease classification">
  <data key="d3">is classified as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="prodromal stages of parkinson's disease">
  <data key="d3">are phases of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="sidransky syndrome">
  <data key="d3">is a variant of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="united states">
  <data key="d3">is suffering from</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="early management">
  <data key="d3">is related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="gba1 gene">
  <data key="d3">is a genetic risk factor for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease" target="glucocerebrosidase (gcase)">
  <data key="d3">is implicated in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease (pd) brain" target="pathogenesis of parkinson's disease">
  <data key="d3">is influenced by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease patients" target="gba1 variant">
  <data key="d3">is found in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="recommended dosage" target="higher dosage">
  <data key="d3">is less than</data>
  <data key="d4">1.0</data>
</edge>
<edge source="research procedures" target="ethical guidelines">
  <data key="d3">followed</data>
  <data key="d4">1.0</data>
</edge>
<edge source="research procedures" target="regulatory standards">
  <data key="d3">followed</data>
  <data key="d4">1.0</data>
</edge>
<edge source="research study" target="findings">
  <data key="d3">reports</data>
  <data key="d4">1.0</data>
</edge>
<edge source="research study" target="study results">
  <data key="d3">influenced by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="research study" target="sensitivity analyses">
  <data key="d3">are conducted in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="research study" target="clinicaltrials.gov">
  <data key="d3">registered on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="research study" target="retrospective data">
  <data key="d3">collected as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="research study" target="study limitations">
  <data key="d3">has</data>
  <data key="d4">1.0</data>
</edge>
<edge source="risk factor" target="parkinson's disease (pd) incidence">
  <data key="d3">is influenced by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="standard dosage" target="150 mg/day">
  <data key="d3">is typical for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="study results" target="patients with gaucher disease">
  <data key="d3">show</data>
  <data key="d4">1.0</data>
</edge>
<edge source="study results" target="evidence">
  <data key="d3">will provide further</data>
  <data key="d4">1.0</data>
</edge>
<edge source="study results" target="peer-reviewed journals">
  <data key="d3">will be published in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="study results" target="scientific conferences">
  <data key="d3">will be presented at</data>
  <data key="d4">1.0</data>
</edge>
<edge source="α-synuclein protein" target="accumulation">
  <data key="d3">is increased in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="alpha-synuclein levels" target="blood sample">
  <data key="d3">analyzed in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="alpha-synuclein levels" target="ambroxol chaperone">
  <data key="d3">modulates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="expectorant" target="ambroxol hydrochloride">
  <data key="d3">is used as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceutical" target="coenzyme q10">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceutical" target="creatine">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceutical" target="dasatinib">
  <data key="d3">is a type of,is a type of</data>
  <data key="d4">2.0</data>
</edge>
<edge source="pharmaceutical" target="deferiprone">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceutical" target="exenatide">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceutical" target="q10">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceutical" target="sodium phenylbutyrate">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceutical" target="tauroursodeoxycholic acid">
  <data key="d3">is a type of,is a type of</data>
  <data key="d4">2.0</data>
</edge>
<edge source="pharmaceutical" target="terazosin">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="therapeutic agent" target="phase 1–3 trials">
  <data key="d3">evaluate</data>
  <data key="d4">1.0</data>
</edge>
<edge source="therapeutic agent" target="gcase enhancers">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="treatment" target="high-dose antibiotics (abx)">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="treatment" target="study duration">
  <data key="d3">is tolerable during</data>
  <data key="d4">1.0</data>
</edge>
<edge source="treatment" target="induced pluripotent stem cell (ipsc)-derived human dopaminergic neurons">
  <data key="d3">is a process involving</data>
  <data key="d4">1.0</data>
</edge>
<edge source="treatment" target="induced pluripotent stem cells (ipscs)">
  <data key="d3">are affected by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="treatment" target="gaucher disease (gd)">
  <data key="d3">requires a</data>
  <data key="d4">1.0</data>
</edge>
<edge source="treatment" target="therapeutic intervention">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="higher dosage" target="over-the-counter (otc) dosage">
  <data key="d3">is lower than</data>
  <data key="d4">1.0</data>
</edge>
<edge source="findings" target="results">
  <data key="d3">Results are often referred to as findings in the context of materials science research.</data>
  <data key="d4">1.0</data>
</edge>
<edge source="4.5 years" target="high-dose antibiotics (abx) + enzyme replacement therapy (ert)">
  <data key="d3">is duration of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="4.5 years" target="study duration">
  <data key="d3">lasted for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotic abx" target="dosage (27 mg/kg/day)">
  <data key="d3">is administered at</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx compound" target="cerebrospinal fluid concentration">
  <data key="d3">measured at</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx compound" target="fibroblast cells">
  <data key="d3">affects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx compound" target="plasma concentration">
  <data key="d3">measured at</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx compound" target="neurodegeneration progression">
  <data key="d3">could delay</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx compound" target="disease progression">
  <data key="d3">slows</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx hydrochloride" target="1.5 mg/kg/day">
  <data key="d3">is initial dose of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx hydrochloride" target="27 mg/kg/day">
  <data key="d3">is maximum dose of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx hydrochloride" target="3 mg/kg/day">
  <data key="d3">is increment of dose</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx hydrochloride" target="daily dosage">
  <data key="d3">is administered as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx hydrochloride" target="oral administration">
  <data key="d3">is a form of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx hydrochloride" target="trough plasma concentration">
  <data key="d3">is measured for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx treatment" target="dosage regimens">
  <data key="d3">increased to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx treatment" target="increased dosage (27 mg/kg/day)">
  <data key="d3">increased dosage</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx treatment" target="initial dosage (21 mg/kg/day)">
  <data key="d3">initial dosage</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx treatment" target="patients with gaucher disease">
  <data key="d3">receive</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx treatment" target="pharmacokinetic parameters">
  <data key="d3">affected by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx treatment" target="trough plasma concentration">
  <data key="d3">measured as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx treatment" target="clinical manifestations">
  <data key="d3">improves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx treatment" target="clinical outcomes">
  <data key="d3">measured after</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx treatment" target="efficacy assessment">
  <data key="d3">evaluated on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx treatment" target="glucocerebrosidase (gcase) function">
  <data key="d3">treatment results in increased</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx treatment" target="safety assessment">
  <data key="d3">evaluated after</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx treatment" target="therapeutic intervention">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx treatment" target="biomarker assessments">
  <data key="d3">measured after</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx treatment" target="gaucher disease (gd)">
  <data key="d3">is explored for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events" target="clinically significant abnormal findings">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events" target="documentation">
  <data key="d3">requires</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events" target="medical treatment">
  <data key="d3">evaluated for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events" target="severity">
  <data key="d3">graded by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events" target="high-dose antibiotics (abx)">
  <data key="d3">has no severe</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events" target="laboratory data">
  <data key="d3">documented in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events" target="nci common toxicity criteria v4">
  <data key="d3">used for grading</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events" target="safety assessment">
  <data key="d3">involves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events" target="dosage regimens">
  <data key="d3">aim to reduce</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events" target="cns_complications">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events" target="venglustat_treatment">
  <data key="d3">associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotic" target="27 mg/kg/day">
  <data key="d3">is administered at a dose of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotic" target="pharmacokinetics">
  <data key="d3">is studied in the context of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotic treatment (abx)" target="27 mg/kg/day">
  <data key="d3">is the effective dosage</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotic treatment (abx)" target="enzyme replacement therapy (ert)">
  <data key="d3">is a method used in treatment</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotic treatment (abx)" target="initial dose (1.5 mg/kg/day)">
  <data key="d3">is initiated at a dose of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotic treatment (abx)" target="maximum dose (27 mg/kg/day)">
  <data key="d3">is escalated up to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotic treatment (abx)" target="neurocognitive function">
  <data key="d3">improves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotic treatment (abx)" target="niemann-pick disease type b (ngd)">
  <data key="d3">is administered for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotic treatment (abx)" target="seizure frequency">
  <data key="d3">decreases</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotic treatment (abx)" target="tolerance">
  <data key="d3">is well</data>
  <data key="d4">1.0</data>
</edge>
<edge source="baseline" target="modified sandhoff scale test (msst) score">
  <data key="d3">is measured at</data>
  <data key="d4">1.0</data>
</edge>
<edge source="baseline" target="seizure frequency">
  <data key="d3">is compared to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="baseline" target="response metrics">
  <data key="d3">is compared to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="baseline gcase activity (pre-ert)" target="peripheral leukocytes">
  <data key="d3">measured in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="baseline gcase activity (pre-ert)" target="patients (pt1–4)">
  <data key="d3">exhibited</data>
  <data key="d4">1.0</data>
</edge>
<edge source="biochemical outcomes" target="secondary endpoints">
  <data key="d3">include</data>
  <data key="d4">1.0</data>
</edge>
<edge source="blood sample" target="pharmacokinetic analysis">
  <data key="d3">used for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="blood sample" target="abx compounds">
  <data key="d3">analyzed in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="blood-brain barrier (bbb)" target="central nervous system (cns) features">
  <data key="d3">do not affect</data>
  <data key="d4">1.0</data>
</edge>
<edge source="blood-brain barrier (bbb)" target="enzyme replacement therapies (erts)">
  <data key="d3">cannot cross</data>
  <data key="d4">1.0</data>
</edge>
<edge source="blood-brain barrier (bbb)" target="small molecules">
  <data key="d3">can cross</data>
  <data key="d4">1.0</data>
</edge>
<edge source="blood-brain barrier (bbb)" target="srt (small molecule receptor therapy)">
  <data key="d3">crosses</data>
  <data key="d4">1.0</data>
</edge>
<edge source="central nervous system" target="progressive neurological manifestations">
  <data key="d3">can cause</data>
  <data key="d4">1.0</data>
</edge>
<edge source="central nervous system" target="misfolded alpha-synuclein">
  <data key="d3">accumulates in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical outcomes" target="secondary endpoints">
  <data key="d3">include</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical outcomes" target="idiopathic parkinson's disease">
  <data key="d3">has</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinically significant abnormal findings" target="laboratory data">
  <data key="d3">found in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="combined therapy" target="enzyme replacement therapy">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="combined therapy" target="enzyme replacement therapy (ert)">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="combined therapy" target="high-dose antibiotics (abx)">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="combined therapy" target="neurological manifestations">
  <data key="d3">aims to improve</data>
  <data key="d4">1.0</data>
</edge>
<edge source="combined therapy" target="efficacy">
  <data key="d3">assessed in relation to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="combined therapy" target="long-term safety">
  <data key="d3">assessed in relation to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dosage concentrations" target="treatment duration (5 days)">
  <data key="d3">are measured over</data>
  <data key="d4">1.0</data>
</edge>
<edge source="efficacy" target="neurological gaucher disease (ngd) patients">
  <data key="d3">is investigated for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="efficacy" target="therapeutic intervention">
  <data key="d3">is a characteristic of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="enzyme replacement therapy" target="ert">
  <data key="d3">is abbreviated as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="enzyme replacement therapy" target="neuronopathic gaucher disease">
  <data key="d3">is a treatment for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="enzyme replacement therapy" target="systemic manifestations">
  <data key="d3">improves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="enzyme replacement therapy (ert)" target="neurological symptoms">
  <data key="d3">might help to arrest the progression of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="enzyme replacement therapy (ert)" target="high-dose antibiotics (abx)">
  <data key="d3">is combined with,is used in combination with</data>
  <data key="d4">2.0</data>
</edge>
<edge source="enzyme replacement therapy (ert)" target="long-term treatment">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="enzyme replacement therapy (ert)" target="safe and effective">
  <data key="d3">is described as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="enzyme replacement therapy (ert)" target="substrate reduction therapy (srt)">
  <data key="d3">are compared to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="enzyme replacement therapy (ert)" target="success">
  <data key="d3">has limited</data>
  <data key="d4">1.0</data>
</edge>
<edge source="enzyme replacement therapy (ert)" target="treatment duration">
  <data key="d3">has duration</data>
  <data key="d4">1.0</data>
</edge>
<edge source="enzyme replacement therapy (ert)" target="gaucher disease type 1 (gd1)">
  <data key="d3">is a treatment for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="enzyme replacement therapy (ert)" target="recombinant glucocerebrosidase">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease (gd)" target="neurological symptoms">
  <data key="d3">is associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease (gd)" target="lyso-gb1">
  <data key="d3">indicates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease (gd)" target="gaucher unit">
  <data key="d3">is treated by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease (gd)" target="gba-associated parkinson's disease (gba-pd)">
  <data key="d3">is related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease (gd)" target="medicine and industry">
  <data key="d3">influences</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease (gd)" target="model of success">
  <data key="d3">is a</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease (gd)" target="pharmaceutical compound">
  <data key="d3">is developed for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease (gd)" target="clinical subtypes">
  <data key="d3">is classified into</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease (gd)" target="carriers">
  <data key="d3">can have</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease (gd)" target="long-term treatment">
  <data key="d3">requires</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease (gd)" target="pharmacological compound (pc)">
  <data key="d3">is specific for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease (gd)" target="therapeutic intervention">
  <data key="d3">is a viable treatment for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease (gd)" target="gba1 gene">
  <data key="d3">is a target for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase (gcase)" target="residual enzymatic activity">
  <data key="d3">enhanced</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase (gcase)" target="endoplasmic reticulum">
  <data key="d3">folding occurs within</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase (gcase)" target="lysosome">
  <data key="d3">activity is increased in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase (gcase)" target="protein levels">
  <data key="d3">promotes increase in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase (gcase)" target="brain tissue">
  <data key="d3">activity is reduced in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase (gcase)" target="enzyme activity">
  <data key="d3">is related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase (gcase)" target="liver tissue">
  <data key="d3">activity is reduced in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase activity" target="biochemical assessments">
  <data key="d3">is assessed alongside</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase activity" target="neurocognitive assessments">
  <data key="d3">is assessed alongside</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebrosidase activity" target="safety assessment">
  <data key="d3">is assessed alongside</data>
  <data key="d4">1.0</data>
</edge>
<edge source="hematological manifestations" target="systemic manifestations">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose antibiotics (abx)" target="long-term treatment">
  <data key="d3">includes,is a type of</data>
  <data key="d4">2.0</data>
</edge>
<edge source="high-dose antibiotics (abx)" target="neurological gaucher disease (ngd) patients">
  <data key="d3">is used in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose antibiotics (abx)" target="neurological symptoms">
  <data key="d3">might help to arrest the progression of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose antibiotics (abx) + enzyme replacement therapy (ert)" target="hematological profile">
  <data key="d3">has no significant change in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose antibiotics (abx) + enzyme replacement therapy (ert)" target="niemann-pick disease type b (ngd)">
  <data key="d3">is treated by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="improvement" target="residual gcase activity">
  <data key="d3">measured by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="lyso-gb1" target="biomarker">
  <data key="d3">is a</data>
  <data key="d4">1.0</data>
</edge>
<edge source="lyso-gb1" target="biomarker for gaucher disease (gd)">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="lyso-gb1" target="progression of gaucher disease (gd)">
  <data key="d3">indicates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="modified sandhoff scale test (msst) score" target="12.3±6">
  <data key="d3">is measured as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="modified sandhoff scale test (msst) score" target="2.5 years of treatment">
  <data key="d3">worsens after</data>
  <data key="d4">1.0</data>
</edge>
<edge source="modified sandhoff scale test (msst) score" target="4.5 years of treatment">
  <data key="d3">improves after</data>
  <data key="d4">1.0</data>
</edge>
<edge source="modified sandhoff scale test (msst) score" target="neurological progression of niemann-pick disease">
  <data key="d3">monitors</data>
  <data key="d4">1.0</data>
</edge>
<edge source="nci common toxicity criteria v4" target="grading">
  <data key="d3">provides criteria for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neurological gaucher disease (ngd) patients" target="long-term clinical safety">
  <data key="d3">is investigated for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neurological manifestations" target="clinical improvement">
  <data key="d3">were not improved or aggravated</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neurological manifestations" target="progression">
  <data key="d3">is related to the</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neurological manifestations" target="patient">
  <data key="d3">suffers from</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neuronopathic gaucher disease" target="ngd">
  <data key="d3">is also known as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neuronopathic gaucher disease" target="therapeutic intervention">
  <data key="d3">requires</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neuronopathic gaucher disease" target="neuronopathic gd (ngd)">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neuronopathic gaucher disease" target="type 2 gaucher disease (gd2)">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neuronopathic gaucher disease" target="gba1-related parkinson's disease">
  <data key="d3">is a disease associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="niemann-pick disease type b (ngd)" target="patient population">
  <data key="d3">is treated in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients with gaucher disease" target="gba1-related parkinson's disease">
  <data key="d3">are related conditions</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients with gaucher disease" target="mutant alleles">
  <data key="d3">have</data>
  <data key="d4">1.0</data>
</edge>
<edge source="peripheral leukocytes" target="residual gcase activity">
  <data key="d3">measured in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmacokinetics" target="pharmacokinetic analysis">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="primary endpoint" target="residual gcase activity">
  <data key="d3">evaluates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="results" target="index case">
  <data key="d3">confirmed in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="results" target="repeated-measures analysis of variance (anova)">
  <data key="d3">used for elaborating</data>
  <data key="d4">1.0</data>
</edge>
<edge source="safety assessment" target="secondary outcomes">
  <data key="d3">are part of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="skeletal manifestations" target="systemic manifestations">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="study duration" target="final phase (last 2 years)">
  <data key="d3">is when improvement observed</data>
  <data key="d4">1.0</data>
</edge>
<edge source="study duration" target="initial phase (2.5 years)">
  <data key="d3">initial phase of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="study duration" target="multicenter phase iii">
  <data key="d3">lasts at least</data>
  <data key="d4">1.0</data>
</edge>
<edge source="study duration" target="24 months">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="study duration" target="26 weeks">
  <data key="d3">ends after</data>
  <data key="d4">1.0</data>
</edge>
<edge source="substrate reduction therapy" target="srt">
  <data key="d3">is abbreviated as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="substrate reduction therapy" target="systemic manifestations">
  <data key="d3">improves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="treatment duration" target="4–14 years">
  <data key="d3">varied from</data>
  <data key="d4">1.0</data>
</edge>
<edge source="treatment duration" target="pba/exendin treatment">
  <data key="d3">is associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="treatment duration" target="investigational medicinal product (imp) treatment">
  <data key="d3">is limited by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="trough plasma concentration" target="10 µmol/l">
  <data key="d3">is target level of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="trough plasma concentration" target="2.3–5.7 µmol/l">
  <data key="d3">ranges from</data>
  <data key="d4">1.0</data>
</edge>
<edge source="trough plasma concentration" target="concentration range (3.2–8.8 µmol/l)">
  <data key="d3">ranges from</data>
  <data key="d4">1.0</data>
</edge>
<edge source="visceral manifestations" target="systemic manifestations">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dosage regimens" target="administration schedules">
  <data key="d3">are adjusted via</data>
  <data key="d4">1.0</data>
</edge>
<edge source="severity" target="neuronopathic gaucher disease (ngd)">
  <data key="d3">is more severe than</data>
  <data key="d4">1.0</data>
</edge>
<edge source="mucolytic agent" target="ambroxol hydrochloride">
  <data key="d3">is a type of,is classified as</data>
  <data key="d4">2.0</data>
</edge>
<edge source="treatment outcomes" target="additive effects">
  <data key="d3">influence</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neurological symptoms" target="neuronopathic gaucher disease (ngd)">
  <data key="d3">are manifestations of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase" target="cerebral tissue">
  <data key="d3">delivered to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase" target="exogenous cerebrospinal fluid (csf)">
  <data key="d3">not merely delivered to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase" target="hibit peptide reporter tag">
  <data key="d3">is labeled with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase" target="lysosomal localization">
  <data key="d3">is associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase" target="protein misfolding">
  <data key="d3">causes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase" target="trafficking obstruction">
  <data key="d3">causes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase" target="immunofluorescence assay">
  <data key="d3">visualizes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase" target="therapeutic target">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="therapeutic intervention" target="human dopaminergic ipscs">
  <data key="d3">receives</data>
  <data key="d4">1.0</data>
</edge>
<edge source="therapeutic intervention" target="research project">
  <data key="d3">can lead to the development of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="therapeutic intervention" target="disease progression">
  <data key="d3">can slow or prevent</data>
  <data key="d4">1.0</data>
</edge>
<edge source="therapeutic intervention" target="trial extension">
  <data key="d3">may involve</data>
  <data key="d4">1.0</data>
</edge>
<edge source="therapeutic intervention" target="symptomatic treatments">
  <data key="d3">are</data>
  <data key="d4">1.0</data>
</edge>
<edge source="therapeutic intervention" target="pharmacological chaperones (pcs)">
  <data key="d3">used as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="therapeutic intervention" target="development process">
  <data key="d3">is part of the process of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="therapeutic intervention" target="viability">
  <data key="d3">describes the quality of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patient population" target="abx 1.2 g/day dosage">
  <data key="d3">are allocated to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="in vitro studies" target="ambroxol hydrochloride">
  <data key="d3">demonstrated efficacy as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="in vitro studies" target="in vivo studies">
  <data key="d3">has discrepancies with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="2009" target="pharmacological chaperone">
  <data key="d3">identified as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="2009" target="meta-analysis">
  <data key="d3">was conducted in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="28-year-old female patient" target="gaucher disease type 3 (gd3) patients">
  <data key="d3">is diagnosed with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events (aes)" target="allergic reaction">
  <data key="d3">includes,includes</data>
  <data key="d4">2.0</data>
</edge>
<edge source="adverse events (aes)" target="cough">
  <data key="d3">includes,includes</data>
  <data key="d4">2.0</data>
</edge>
<edge source="adverse events (aes)" target="disease progression">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events (aes)" target="dizziness">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events (aes)" target="efficacy data">
  <data key="d3">are collected alongside</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events (aes)" target="gaucher disease type 3 (gd3) patients">
  <data key="d3">monitored for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events (aes)" target="mild and transient effects">
  <data key="d3">are characterized as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events (aes)" target="mild proteinuria">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events (aes)" target="minor bowel discomfort">
  <data key="d3">includes,includes</data>
  <data key="d4">2.0</data>
</edge>
<edge source="adverse events (aes)" target="phase 3 eliglustat engage trial">
  <data key="d3">assesses</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adverse events (aes)" target="reported">
  <data key="d3">are not present</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol hydrochloride" target="cough suppressant">
  <data key="d3">is used as,functions as</data>
  <data key="d4">2.0</data>
</edge>
<edge source="ambroxol hydrochloride" target="gba-parkinson disease">
  <data key="d3">is studied for use in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol hydrochloride" target="over-the-counter (otc) dosage">
  <data key="d3">requires higher than</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol hydrochloride" target="over-the-counter medication">
  <data key="d3">is available as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol hydrochloride" target="pharmaceutical compound">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol hydrochloride" target="pharmacological chaperone">
  <data key="d3">serves as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol hydrochloride" target="healthcare professionals">
  <data key="d3">evaluate</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol hydrochloride" target="increased dosage">
  <data key="d3">required for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol hydrochloride" target="mutant glucocerebrosidase">
  <data key="d3">is targeted by,is assisted by</data>
  <data key="d4">2.0</data>
</edge>
<edge source="biotech company" target="drug patent">
  <data key="d3">holds</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical registries" target="multi-center, multi-national">
  <data key="d3">are characterized as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinicaltrials.gov" target="identifier">
  <data key="d3">has</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinicaltrials.gov" target="active studies">
  <data key="d3">lists</data>
  <data key="d4">1.0</data>
</edge>
<edge source="countries" target="13 different">
  <data key="d3">are</data>
  <data key="d4">1.0</data>
</edge>
<edge source="countries" target="research centers">
  <data key="d3">contributed from</data>
  <data key="d4">1.0</data>
</edge>
<edge source="countries" target="over-the-counter (otc) medication">
  <data key="d3">is used in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="eight patients" target="profile of adverse events (aes)">
  <data key="d3">is not different from</data>
  <data key="d4">1.0</data>
</edge>
<edge source="enzyme replacement therapies (erts)" target="lysosomal storage diseases">
  <data key="d3">develops for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="enzyme replacement therapies (erts)" target="research and development">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="experimental drugs" target="over-the-counter (otc)">
  <data key="d3">is a status of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="experimental drugs" target="safety concerns">
  <data key="d3">raises</data>
  <data key="d4">1.0</data>
</edge>
<edge source="experimental drugs" target="healthcare professionals">
  <data key="d3">are reluctant to recommend</data>
  <data key="d4">1.0</data>
</edge>
<edge source="fatigue_level" target="reduced_level">
  <data key="d3">can be</data>
  <data key="d4">1.0</data>
</edge>
<edge source="first 41 patients" target="median age">
  <data key="d3">have</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease type 1 (gd1)" target="gba-associated parkinson's disease (gba-pd)">
  <data key="d3">received ambroxol as single therapy</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease type 1 (gd1)" target="neuronopathic gaucher disease (ngd)">
  <data key="d3">is a condition related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease type 1 (gd1)" target="pilot study">
  <data key="d3">involves patients with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease type 2" target="disease">
  <data key="d3">is a form of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease type 2" target="patient">
  <data key="d3">is diagnosed with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease-specific therapy" target="history of splenectomy">
  <data key="d3">is included in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher unit" target="shaare zedek medical center">
  <data key="d3">is part of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba-associated parkinson's disease (gba-pd)" target="disease-modifying therapies">
  <data key="d3">awaits approval for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba-associated parkinson's disease (gba-pd)" target="neurodegenerative disease (ngd)">
  <data key="d3">are conditions related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba-associated parkinson's disease (gba-pd)" target="age of onset">
  <data key="d3">has early age at</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba-associated parkinson's disease (gba-pd)" target="akinetic-rigid phenotype">
  <data key="d3">exhibits</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba-associated parkinson's disease (gba-pd)" target="dyskinesias">
  <data key="d3">has high risk of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba-associated parkinson's disease (gba-pd)" target="levodopa treatment">
  <data key="d3">has excellent response to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba-associated parkinson's disease (gba-pd)" target="motor fluctuations">
  <data key="d3">has high risk of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba-associated parkinson's disease (gba-pd)" target="dementia risk">
  <data key="d3">has higher risk of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba-associated parkinson's disease (gba-pd)" target="non-carrier individuals">
  <data key="d3">is compared to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba-associated parkinson's disease (gba-pd)" target="survival rate">
  <data key="d3">has reduced</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gd2" target="disease">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gd2" target="patient 14">
  <data key="d3">is diagnosed with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="generic drug forms" target="online purchase">
  <data key="d3">can be</data>
  <data key="d4">1.0</data>
</edge>
<edge source="generic drug forms" target="pharmaceutical companies">
  <data key="d3">show no interest due to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="healthcare professionals" target="developed nations">
  <data key="d3">are located in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="healthcare professionals" target="safety concerns">
  <data key="d3">affect</data>
  <data key="d4">1.0</data>
</edge>
<edge source="healthcare providers" target="preliminary research findings">
  <data key="d3">may encourage</data>
  <data key="d4">1.0</data>
</edge>
<edge source="healthcare providers" target="unproven approach">
  <data key="d3">do not recommend</data>
  <data key="d4">1.0</data>
</edge>
<edge source="identifier" target="nct04388969">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ii-reg" target="efficacy monitoring">
  <data key="d3">monitors</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ii-reg" target="international registry">
  <data key="d3">fills gap until</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ii-reg" target="retrospective data collection">
  <data key="d3">serves as a platform for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ii-reg" target="safety monitoring">
  <data key="d3">monitors</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ii-reg" target="patients worldwide">
  <data key="d3">participate in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="individual cases" target="myoclonic epilepsy">
  <data key="d3">may show improvement in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="infants" target="type 2 gaucher disease (gd2)">
  <data key="d3">are diagnosed with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="international registry" target="launch">
  <data key="d3">expected to be</data>
  <data key="d4">1.0</data>
</edge>
<edge source="investigator-initiated registry" target="registry ii-reg">
  <data key="d3">is the name of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="investigator-initiated registry" target="disease-specific treatment">
  <data key="d3">is established for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="investigator-initiated registry" target="real-world evidence">
  <data key="d3">provides</data>
  <data key="d4">1.0</data>
</edge>
<edge source="mutant glucocerebrosidase" target="endoplasmic reticulum">
  <data key="d3">misfolds in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="myoclonic epilepsy" target="children">
  <data key="d3">affects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="myoclonic epilepsy" target="neuronopathic gd">
  <data key="d3">is a manifestation of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neurological_status" target="stable_or_improved">
  <data key="d3">can be</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neuronopathic gaucher disease (ngd)" target="high-dose ert">
  <data key="d3">receives</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neuronopathic gaucher disease (ngd)" target="specific treatment">
  <data key="d3">lack</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neuronopathic gaucher disease (ngd)" target="pharmaceutical compound">
  <data key="d3">is a treatment for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neuronopathic gaucher disease (ngd)" target="small molecules">
  <data key="d3">impacts</data>
  <data key="d4">1.0</data>
</edge>
<edge source="niemann-pick disease type c (ngd)" target="approved therapeutics">
  <data key="d3">awaits approval for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="niemann-pick disease type c (ngd)" target="specific treatment">
  <data key="d3">has no</data>
  <data key="d4">1.0</data>
</edge>
<edge source="niemann-pick disease type c (ngd)" target="therapeutics">
  <data key="d3">target</data>
  <data key="d4">1.0</data>
</edge>
<edge source="off-label use" target="official monitoring">
  <data key="d3">is optional for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patient" target="independent walking">
  <data key="d3">achieves through</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patient" target="treatment response">
  <data key="d3">achieves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patient" target="refractory myoclonic epilepsy">
  <data key="d3">affects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patient" target="severe ataxia">
  <data key="d3">affects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patient" target="self-administers">
  <data key="d3">does</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patient cohorts" target="reported cases">
  <data key="d3">contribute to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceutical compound" target="coenzyme">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceutical compound" target="creatine">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceutical compound" target="deferiprone">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceutical compound" target="exenatide">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceutical compound" target="sodium phenylbutyrate">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceutical compound" target="terazosin">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceutical industry" target="interest">
  <data key="d3">has in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceutical industry" target="research and development">
  <data key="d3">invests in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="phase 3 eliglustat engage trial" target="placebo arm">
  <data key="d3">reported in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="phase ii regulatory study (ii-reg)" target="safety data">
  <data key="d3">prioritizes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="physical_activity" target="increased_level">
  <data key="d3">can be</data>
  <data key="d4">1.0</data>
</edge>
<edge source="preliminary efficacy data" target="real-world evidence">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="protocol identifier" target="0097-20-szmc">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="real-world evidence" target="safety data">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="real-world observational data" target="safety and efficacy">
  <data key="d3">needed for assessing</data>
  <data key="d4">1.0</data>
</edge>
<edge source="registry" target="safety and efficacy">
  <data key="d3">allows understanding of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="registry" target="shaare zedek medical center">
  <data key="d3">was approved by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="registry" target="level of evidence">
  <data key="d3">upgrades level of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="research centers" target="13">
  <data key="d3">are</data>
  <data key="d4">1.0</data>
</edge>
<edge source="retrospective data" target="unified case report form (crf)">
  <data key="d3">is collected using</data>
  <data key="d4">1.0</data>
</edge>
<edge source="safety and efficacy" target="regulatory approval">
  <data key="d3">are criteria for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="small molecules" target="allosteric activator">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="small molecules" target="gcase-l444p variant">
  <data key="d3">increase levels of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="small molecules" target="lysosomal activity">
  <data key="d3">is enhanced by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="small molecules" target="screening process">
  <data key="d3">identified</data>
  <data key="d4">1.0</data>
</edge>
<edge source="spleen volumes" target="reduction">
  <data key="d3">can</data>
  <data key="d4">1.0</data>
</edge>
<edge source="therapeutics" target="biological pathways">
  <data key="d3">affect</data>
  <data key="d4">1.0</data>
</edge>
<edge source="therapeutics" target="mitochondrial dysfunction">
  <data key="d3">target</data>
  <data key="d4">1.0</data>
</edge>
<edge source="therapeutics" target="neuroinflammation">
  <data key="d3">target</data>
  <data key="d4">1.0</data>
</edge>
<edge source="therapeutics" target="α-synuclein accumulation">
  <data key="d3">target</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmacological chaperone" target="gba1-related parkinson's disease">
  <data key="d3">is a condition treated by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmacological chaperone" target="genetic variants">
  <data key="d3">is unlikely to be equally effective for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="disease progression" target="enhanced efficacy">
  <data key="d3">demonstrated by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="disease progression" target="cerebrospinal fluid (csf) neurodegeneration biomarkers">
  <data key="d3">used as surrogate markers of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="disease progression" target="neuroimaging biomarkers">
  <data key="d3">used as surrogate markers of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="over-the-counter (otc) medication" target="boehringer-ingelheim">
  <data key="d3">commercializes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="over-the-counter (otc) medication" target="united states">
  <data key="d3">is an exception for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="drug development" target="hibit-gcase-l444p assay">
  <data key="d3">utility for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="substrate reduction therapy (srt)" target="consideration">
  <data key="d3">is subject of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="substrate reduction therapy (srt)" target="gba1-related parkinson's disease">
  <data key="d3">is treatment for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="substrate reduction therapy (srt)" target="treatment failure">
  <data key="d3">has</data>
  <data key="d4">1.0</data>
</edge>
<edge source="affected patients" target="neuronopathic gd">
  <data key="d3">affects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="disease-modifying therapies" target="global research initiatives">
  <data key="d3">aim to establish</data>
  <data key="d4">1.0</data>
</edge>
<edge source="1-methyl-4-phenylpyridinium (mpp+)" target="cytotoxicity">
  <data key="d3">induces</data>
  <data key="d4">1.0</data>
</edge>
<edge source="1-methyl-4-phenylpyridinium (mpp+)" target="induced pluripotent stem cells (ipscs)">
  <data key="d3">is treatment for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="1-methyl-4-phenylpyridinium (mpp+)" target="neurodegeneration">
  <data key="d3">is linked to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="1-methyl-4-phenylpyridinium (mpp+)" target="neurotoxin">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="1-methyl-4-phenylpyridinium (mpp+)" target="toxicity">
  <data key="d3">induces</data>
  <data key="d4">1.0</data>
</edge>
<edge source="1-methyl-4-phenylpyridinium (mpp+)" target="induced pluripotent stem cell (ipsc)-derived human dopaminergic neurons">
  <data key="d3">are treated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="1-methyl-4-phenylpyridinium (mpp+)" target="wild-type human dopaminergic induced pluripotent stem cell (ipsc) line">
  <data key="d3">is treated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="1-methyl-4-phenylpyridinium (mpp+)" target="dopaminergic induced pluripotent stem cells (ipscs)">
  <data key="d3">treated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="active compounds" target="biological pathways">
  <data key="d3">target</data>
  <data key="d4">1.0</data>
</edge>
<edge source="active compounds" target="combination therapy">
  <data key="d3">contains</data>
  <data key="d4">1.0</data>
</edge>
<edge source="additive effects" target="combinations">
  <data key="d3">are observed in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="additive effects" target="combinations of compounds">
  <data key="d3">show</data>
  <data key="d4">1.0</data>
</edge>
<edge source="additive effects" target="identified treatment combinations">
  <data key="d3">show</data>
  <data key="d4">1.0</data>
</edge>
<edge source="additive neuroprotective effect" target="pharmaceutical compounds">
  <data key="d3">is superior to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adenosine triphosphate (atp)" target="experimental conditions">
  <data key="d3">is a factor in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="adenosine triphosphate (atp)" target="human microglial cell line">
  <data key="d3">is treated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="α-synuclein triplication model" target="human cell line">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="α-synuclein triplication model" target="human dopaminergic ipscs">
  <data key="d3">affects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="α-synuclein triplication model" target="cell line">
  <data key="d3">is modeled by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="anti-inflammatory properties" target="human microglia cells">
  <data key="d3">exhibited by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="anti-inflammatory properties" target="human microglial cell line">
  <data key="d3">assesses</data>
  <data key="d4">1.0</data>
</edge>
<edge source="biological pathways" target="neurodegenerative processes">
  <data key="d3">contributes to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="biological pathways" target="pharmaceuticals">
  <data key="d3">targets</data>
  <data key="d4">1.0</data>
</edge>
<edge source="calcium excitotoxicity" target="energy depletion">
  <data key="d3">leads to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="calcium excitotoxicity" target="mitochondrial function">
  <data key="d3">disrupts</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cell" target="energy buffering">
  <data key="d3">involves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cell" target="induced pluripotent stem cells (ipscs)">
  <data key="d3">are a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cell proliferation" target="treated cells">
  <data key="d3">is higher in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cell proliferation" target="control cells">
  <data key="d3">is compared to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cell proliferation" target="significant increase">
  <data key="d3">indicates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cell proliferation" target="td16 parkinson's dopaminergic cell line">
  <data key="d3">shows increase in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="coenzyme q10" target="atp production">
  <data key="d3">regulates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="coenzyme q10" target="free radical generation">
  <data key="d3">reduces</data>
  <data key="d4">1.0</data>
</edge>
<edge source="combination medications" target="neuroprotective effect">
  <data key="d3">can exert</data>
  <data key="d4">1.0</data>
</edge>
<edge source="combination therapy" target="pd patients">
  <data key="d3">is feasible for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="combination therapy" target="pharmaceuticals">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="combination therapy" target="pragmatic strategy">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="combination therapy" target="synergistic effects">
  <data key="d3">demonstrates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="control cells" target="significant increase">
  <data key="d3">is relative to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="creatine" target="energy buffering">
  <data key="d3">plays a role in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="creatine" target="natural supplement">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cytotoxicity" target="cellular damage">
  <data key="d3">results in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dasatinib" target="5 nm concentration">
  <data key="d3">has dose of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dasatinib" target="c-abl inhibitor">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dasatinib" target="chronic myeloid leukemia">
  <data key="d3">is used for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dasatinib" target="combination testing">
  <data key="d3">is part of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dasatinib" target="ipd td16 cell line">
  <data key="d3">is tested in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dasatinib" target="neurodegenerative disease">
  <data key="d3">targets pathways involved in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dasatinib" target="dose-response experiment">
  <data key="d3">informs</data>
  <data key="d4">1.0</data>
</edge>
<edge source="deferiprone" target="blood-brain barrier">
  <data key="d3">passes through</data>
  <data key="d4">1.0</data>
</edge>
<edge source="deferiprone" target="excess brain iron">
  <data key="d3">chelates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="deferiprone" target="iron overload disorders">
  <data key="d3">is therapy for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="diverse mechanisms of action" target="pharmaceuticals">
  <data key="d3">is a characteristic of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dopaminergic induced pluripotent stem cells (ipscs)" target="mpp+ treatment">
  <data key="d3">is treated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dopaminergic induced pluripotent stem cells (ipscs)" target="human cell line">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dopaminergic neurons" target="dopamine">
  <data key="d3">produce</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dopaminergic neurons" target="neurotransmission">
  <data key="d3">is involved in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dopaminergic neurons" target="neurotransmitter">
  <data key="d3">are associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dopaminergic neurons" target="induced pluripotent stem cells (ipscs)">
  <data key="d3">are a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dopaminergic neurons" target="neurite branching">
  <data key="d3">improves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dopaminergic neurons" target="neurite outgrowth">
  <data key="d3">improves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dopaminergic neurons" target="neurofilament heavy chain (nfh)">
  <data key="d3">improves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dopaminergic neurons" target="wild-type human dopaminergic induced pluripotent stem cell (ipsc) line">
  <data key="d3">is derived from</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dopaminergic neurons" target="alpha-synuclein aggregation">
  <data key="d3">occurs in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dopaminergic neurons" target="cell death">
  <data key="d3">leads to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dopaminergic neurons" target="glucosylceramide">
  <data key="d3">do not accumulate</data>
  <data key="d4">1.0</data>
</edge>
<edge source="dopaminergic neurons" target="substantia nigra region">
  <data key="d3">are counted in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="drug candidate" target="clinical potential">
  <data key="d3">offers</data>
  <data key="d4">1.0</data>
</edge>
<edge source="drug candidate" target="neuroprotective properties">
  <data key="d3">capable of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="drug combinations" target="evaluation">
  <data key="d3">involves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="drug combinations" target="mechanisms of action">
  <data key="d3">utilize</data>
  <data key="d4">1.0</data>
</edge>
<edge source="drug combinations" target="mechanistic targets">
  <data key="d3">target</data>
  <data key="d4">1.0</data>
</edge>
<edge source="drug combinations" target="drug repurposing">
  <data key="d3">designed to assess</data>
  <data key="d4">1.0</data>
</edge>
<edge source="drug combinations" target="nine pharmaceuticals">
  <data key="d3">evaluated for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="drug combinations" target="pharmaceuticals">
  <data key="d3">are identified as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="drug combinations" target="synergistic efficacy">
  <data key="d3">demonstrates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="energy depletion" target="neurodegeneration">
  <data key="d3">contributes to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="exenatide" target="clinical endpoint">
  <data key="d3">showed improvement in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="exenatide" target="glp-1 (glucagon-like peptide-1)">
  <data key="d3">activates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="exenatide" target="microglial deactivation">
  <data key="d3">may act as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="exenatide" target="type 2 diabetes mellitus">
  <data key="d3">is therapy for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="experimental conditions" target="td16 parkinson's dopaminergic cell line">
  <data key="d3">affect</data>
  <data key="d4">1.0</data>
</edge>
<edge source="experimental conditions" target="lipopolysaccharide (lps)">
  <data key="d3">is a factor in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="experimental conditions" target="parkinson's disease cell lines">
  <data key="d3">are studied under</data>
  <data key="d4">1.0</data>
</edge>
<edge source="forty-four combinations" target="pharmaceuticals">
  <data key="d3">evaluated</data>
  <data key="d4">1.0</data>
</edge>
<edge source="free radical generation" target="atp production">
  <data key="d3">is related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="global research initiatives" target="neuroprotective therapies">
  <data key="d3">aim to establish</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glycolytic pathway" target="cellular atp production">
  <data key="d3">increases</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glycolytic pathway" target="phosphoglycerate kinase 1">
  <data key="d3">stimulates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="human dopaminergic ipscs" target="neurotoxicity">
  <data key="d3">are affected by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="human dopaminergic ipscs" target="neurite outgrowth">
  <data key="d3">is measured in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="human dopaminergic pluripotent stem cells" target="neuroprotection">
  <data key="d3">exhibit</data>
  <data key="d4">1.0</data>
</edge>
<edge source="human dopaminergic pluripotent stem cells" target="mpp+ toxin">
  <data key="d3">affects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="human microglial cell line" target="lipopolysaccharide (lps)">
  <data key="d3">is treated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="human microglia cells" target="neuroinflammation assessment">
  <data key="d3">assessed for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="idiopathic parkinson's disease" target="gba1-related parkinson's disease">
  <data key="d3">is compared to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="idiopathic parkinson's disease" target="sidransky syndrome">
  <data key="d3">is compared to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="idiopathic parkinson's disease" target="pharmacological chaperones">
  <data key="d3">are used to treat</data>
  <data key="d4">1.0</data>
</edge>
<edge source="in vitro models" target="pd pathology diversity">
  <data key="d3">explains</data>
  <data key="d4">1.0</data>
</edge>
<edge source="in vitro models" target="pharmaceutical compounds">
  <data key="d3">assessed in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="induced pluripotent stem cell (ipsc)-derived human dopaminergic neurons" target="human">
  <data key="d3">are derived from</data>
  <data key="d4">1.0</data>
</edge>
<edge source="induced pluripotent stem cell (ipsc)-derived human dopaminergic neurons" target="neurons">
  <data key="d3">are a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="induced pluripotent stem cells (ipscs)" target="research">
  <data key="d3">is used in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="induced pluripotent stem cells (ipscs)" target="ipd td16 cell line">
  <data key="d3">is tested on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="induced pluripotent stem cells (ipscs)" target="sporadic parkinson's disease human ipsc line">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="initial screening" target="pharmaceuticals">
  <data key="d3">utilized for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ipd td16 cell line" target="differentiation process">
  <data key="d3">undergoes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ipd td16 cell line" target="testing procedure">
  <data key="d3">is conducted on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="iron accumulation" target="microglial activation">
  <data key="d3">activates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="iron accumulation" target="substantia nigra">
  <data key="d3">occurs in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="iron overload" target="metabolic pathways">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="microglial activation" target="neuroinflammation">
  <data key="d3">causes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="misfolded alpha-synuclein" target="neurodegeneration">
  <data key="d3">contributes to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="mitochondrial dysfunction" target="metabolic pathways">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="mitochondrial dysfunction" target="neuronal damage">
  <data key="d3">contributes to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="mpp+ toxin" target="neuroprotection">
  <data key="d3">counteracts</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neurite outgrowth" target="branching points">
  <data key="d3">are increased by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neurodegeneration" target="pharmacotherapy">
  <data key="d3">cannot be addressed with just one</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neurodegeneration" target="cell death">
  <data key="d3">is a form of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neurodegeneration" target="gba1-related parkinson's disease">
  <data key="d3">contributes to the development of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neurodegenerative disease" target="pathways">
  <data key="d3">involves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neurodegenerative disease" target="q10">
  <data key="d3">targets pathways involved in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neurodegenerative disease" target="tauroursodeoxycholic acid">
  <data key="d3">targets pathways involved in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neurodegenerative disease" target="various pathways">
  <data key="d3">are involved in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neurodegenerative disease" target="common">
  <data key="d3">is second most</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neuroimmune responses" target="neuroinflammation">
  <data key="d3">triggers</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neuroinflammation" target="inflammatory pathways">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neuroinflammation" target="neuronal damage">
  <data key="d3">mediates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neuroinflammation" target="reactive oxygen species (ros)">
  <data key="d3">generates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neuroprotection" target="pharmaceuticals">
  <data key="d3">screen for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neuroprotective properties" target="pharmaceuticals">
  <data key="d3">demonstrated by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pathophysiological processes" target="pharmaceuticals">
  <data key="d3">targets</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pathophysiological processes" target="alpha-synuclein aggregation">
  <data key="d3">promotes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pathophysiological processes" target="homeostasis">
  <data key="d3">failure leads to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pathophysiological processes" target="inflammation">
  <data key="d3">promotes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pba/exendin treatment" target="28-day duration">
  <data key="d3">is administered for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pba/exendin treatment" target="td16 parkinson's dopaminergic cell line">
  <data key="d3">is treated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pba/exendin treatment" target="α-synuclein triplication cell line">
  <data key="d3">is treated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="personalized medicine" target="potential solutions">
  <data key="d3">is potential for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceutical compounds" target="in vivo models">
  <data key="d3">assessed in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceuticals" target="mechanisms of action">
  <data key="d3">have</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceuticals" target="pathophysiological mechanisms">
  <data key="d3">affect</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmaceuticals" target="testing">
  <data key="d3">becomes challenging in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="phenylbutyrate" target="clinical endpoint">
  <data key="d3">showed improvement in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="phosphoglycerate kinase 1" target="terazosin">
  <data key="d3">enhances activity of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="reactive oxygen species (ros)" target="oxidative stress pathways">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="sodium phenylbutyrate" target="fda-approved drug">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="sodium phenylbutyrate" target="glutamine levels">
  <data key="d3">reduces</data>
  <data key="d4">1.0</data>
</edge>
<edge source="sodium phenylbutyrate" target="plasma ammonia levels">
  <data key="d3">reduces</data>
  <data key="d4">1.0</data>
</edge>
<edge source="sodium phenylbutyrate" target="urea cycle disorders">
  <data key="d3">treats</data>
  <data key="d4">1.0</data>
</edge>
<edge source="sodium phenylbutyrate" target="alpha-synuclein aggregation">
  <data key="d3">prevents misfolding of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="substantia nigra" target="excess brain iron">
  <data key="d3">is located in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="tauroursodeoxycholic acid" target="clinical endpoint">
  <data key="d3">showed improvement in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="tauroursodeoxycholic acid" target="endogenous bile acid">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="tauroursodeoxycholic acid" target="neuroprotective agent">
  <data key="d3">acts as a</data>
  <data key="d4">1.0</data>
</edge>
<edge source="terazosin" target="benign prostatic hyperplasia">
  <data key="d3">treats</data>
  <data key="d4">1.0</data>
</edge>
<edge source="terazosin" target="fda-approved drug">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="terazosin" target="hypertension">
  <data key="d3">treats</data>
  <data key="d4">1.0</data>
</edge>
<edge source="tudca and exendin treatment" target="90 days duration">
  <data key="d3">is treated for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="tudca and exendin treatment" target="α-synuclein triplication cell line">
  <data key="d3">is treated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="tudca and pba treatment" target="90 days duration">
  <data key="d3">is treated for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="tudca and pba treatment" target="α-synuclein triplication cell line">
  <data key="d3">is treated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="two-week differentiation period" target="differentiation process">
  <data key="d3">is duration of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="wild-type human dopaminergic induced pluripotent stem cell (ipsc) line" target="model organism">
  <data key="d3">is a</data>
  <data key="d4">1.0</data>
</edge>
<edge source="wild-type human dopaminergic induced pluripotent stem cell (ipsc) line" target="research model">
  <data key="d3">serves as a</data>
  <data key="d4">1.0</data>
</edge>
<edge source="α-synuclein triplication cell line" target="60 days post-maturation">
  <data key="d3">is matured to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="α-synuclein triplication cell line" target="tudca, exendin, and pba treatment">
  <data key="d3">is treated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="combinations" target="pharmacological agents">
  <data key="d3">interact synergistically with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="blood-brain barrier" target="low-intensity focused ultrasound (lifu)">
  <data key="d3">temporarily opens</data>
  <data key="d4">1.0</data>
</edge>
<edge source="blood-brain barrier" target="reduction therapy">
  <data key="d3">is capable of crossing</data>
  <data key="d4">1.0</data>
</edge>
<edge source="mechanisms of action" target="bioactive compounds">
  <data key="d3">have</data>
  <data key="d4">1.0</data>
</edge>
<edge source="mechanisms of action" target="final hit compounds">
  <data key="d3">represented several</data>
  <data key="d4">1.0</data>
</edge>
<edge source="5%–14%" target="patients with parkinson's disease (pd)">
  <data key="d3">of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx formulation" target="standard treatment dose">
  <data key="d3">is standard for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx formulation" target="tablet count">
  <data key="d3">is limited to 6</data>
  <data key="d4">1.0</data>
</edge>
<edge source="abx formulation" target="patient compliance">
  <data key="d3">is increased by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ambroxol chaperone" target="gcase activity levels">
  <data key="d3">increases</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics" target="cognitive dysfunction">
  <data key="d3">reduces progression of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics" target="motor symptoms">
  <data key="d3">reduces progression of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics" target="non-motor symptoms">
  <data key="d3">reduces progression of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics" target="quality of life">
  <data key="d3">worsens</data>
  <data key="d4">1.0</data>
</edge>
<edge source="antibiotics" target="subclinical neuroprotective effects">
  <data key="d3">detects using</data>
  <data key="d4">1.0</data>
</edge>
<edge source="beta-glucocerebrosidase (gcase)" target="glucosylceramide">
  <data key="d3">breaks down</data>
  <data key="d4">1.0</data>
</edge>
<edge source="brain mri imaging" target="subclinical neuroprotective effects">
  <data key="d3">used to detect</data>
  <data key="d4">1.0</data>
</edge>
<edge source="changes in moca scale score" target="clinical efficacy">
  <data key="d3">indicates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical study" target="good clinical practice">
  <data key="d3">is conducted according to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical study" target="study protocols">
  <data key="d3">has</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cognitive assessments" target="secondary outcomes">
  <data key="d3">are part of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cognitive impairment" target="moca scale score">
  <data key="d3">assesses changes in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cognitive impairment" target="high-dose oral antibiotics">
  <data key="d3">reduces progression of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cognitive impairment" target="primary outcome">
  <data key="d3">focuses on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucosylceramide" target="ceramide">
  <data key="d3">is broken down to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucosylceramide" target="glucose">
  <data key="d3">is broken down to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucosylceramide" target="substrate">
  <data key="d3">is</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose oral antibiotics" target="clinical efficacy">
  <data key="d3">evaluates,compared with,aims to detect</data>
  <data key="d4">3.0</data>
</edge>
<edge source="high-dose oral antibiotics" target="moca scale score">
  <data key="d3">evaluates impact on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose oral antibiotics" target="outcome measurements">
  <data key="d3">is part of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="high-dose oral antibiotics" target="primary outcome">
  <data key="d3">is related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="material types" target="ceramics">
  <data key="d3">Material Types also consist of Ceramics, known for their hardness and thermal resistance.</data>
  <data key="d4">1.0</data>
</edge>
<edge source="material types" target="metals">
  <data key="d3">Material Types can be categorized into Metals, which are known for their conductivity and malleability.</data>
  <data key="d4">1.0</data>
</edge>
<edge source="material types" target="polymers">
  <data key="d3">Material Types include Polymers, which are characterized by their long molecular chains and flexibility.</data>
  <data key="d4">1.0</data>
</edge>
<edge source="materials science" target="biomaterials">
  <data key="d3">Biomaterials are materials designed for medical applications, an important focus area in materials science</data>
  <data key="d4">1.0</data>
</edge>
<edge source="materials science" target="ceramics">
  <data key="d3">Ceramics is a branch of materials science that deals with the study of inorganic, non-metallic materials.,Ceramics are a category of materials studied within materials science, focusing on inorganic, non-metallic solids.</data>
  <data key="d4">2.0</data>
</edge>
<edge source="materials science" target="composite materials">
  <data key="d3">Composite Materials are made from two or more constituent materials with significantly different physical or chemical properties.,Composite materials are made from two or more constituent materials with significantly different physical or chemical properties.</data>
  <data key="d4">2.0</data>
</edge>
<edge source="materials science" target="electronic materials">
  <data key="d3">Electronic materials are critical in materials science, particularly for applications in electronics and semiconductors</data>
  <data key="d4">1.0</data>
</edge>
<edge source="materials science" target="metallurgy">
  <data key="d3">Metallurgy is a subfield of materials science focused on the properties and applications of metals.,Metallurgy is a branch of materials science that deals with the physical and chemical behavior of metallic elements.</data>
  <data key="d4">2.0</data>
</edge>
<edge source="materials science" target="nanomaterials">
  <data key="d3">Nanomaterials are materials with structural components smaller than 100 nanometers, studied within materials science.,Nanomaterials are a subfield of materials science focusing on materials with structures at the nanoscale.</data>
  <data key="d4">2.0</data>
</edge>
<edge source="materials science" target="polymers">
  <data key="d3">Polymers are a major class of materials within materials science, characterized by long molecular chains</data>
  <data key="d4">1.0</data>
</edge>
<edge source="materials science" target="conclusion">
  <data key="d3">The conclusion summarizes findings and implications derived from research in materials science.</data>
  <data key="d4">1.0</data>
</edge>
<edge source="materials science" target="material characterization">
  <data key="d3">Material characterization is a key process in materials science for understanding the properties and structure of materials.</data>
  <data key="d4">1.0</data>
</edge>
<edge source="materials science" target="materials engineering">
  <data key="d3">Materials engineering applies principles of materials science to design and develop new materials.</data>
  <data key="d4">1.0</data>
</edge>
<edge source="materials science" target="polymer science">
  <data key="d3">Polymer Science is a subfield of materials science that studies the synthesis, characterization, and applications of polymers.,Polymer science is a field within materials science that studies the properties and applications of polymers.</data>
  <data key="d4">2.0</data>
</edge>
<edge source="mild cognitive impairment (mci)" target="primary outcome measures">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="montreal cognitive assessment (moca) score" target="primary outcome measures">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="motor evaluations" target="secondary outcomes">
  <data key="d3">are part of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="motor symptoms" target="validated assessment scales">
  <data key="d3">assess</data>
  <data key="d4">1.0</data>
</edge>
<edge source="multicenter phase iii" target="research initiative">
  <data key="d3">is a part of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="non-motor symptoms" target="validated assessment scales">
  <data key="d3">assess</data>
  <data key="d4">1.0</data>
</edge>
<edge source="outcomes" target="positive results">
  <data key="d3">can lead to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients with parkinson's disease (pd)" target="global population">
  <data key="d3">are estimated at</data>
  <data key="d4">1.0</data>
</edge>
<edge source="patients with parkinson's disease (pd)" target="gba1 gene">
  <data key="d3">is related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pilot studies" target="glucocerebrosidase (gcase) function">
  <data key="d3">explore effects on</data>
  <data key="d4">1.0</data>
</edge>
<edge source="primary objective" target="clinical efficacy">
  <data key="d3">aims to measure</data>
  <data key="d4">1.0</data>
</edge>
<edge source="psychiatric assessments" target="secondary outcomes">
  <data key="d3">are part of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="registration identifiers" target="eudract 2021-004565-13">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="registration identifiers" target="nct05287503">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="symptom progression" target="neurodegeneration biomarkers">
  <data key="d3">is associated with changes in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="tolerability assessments" target="secondary outcomes">
  <data key="d3">are part of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical manifestations" target="reversibility">
  <data key="d3">demonstrated in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cognitive dysfunction" target="hypokinetic movement disorder">
  <data key="d3">has higher prevalence in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="protein levels" target="gcase-l444p variant">
  <data key="d3">are enhanced by,affects</data>
  <data key="d4">2.0</data>
</edge>
<edge source="1 million individuals" target="10.4%">
  <data key="d3">represents</data>
  <data key="d4">1.0</data>
</edge>
<edge source="10.4%" target="rare disease classification">
  <data key="d3">falls within the definition of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="10.4%" target="total population">
  <data key="d3">is percentage of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="10.4% positive rate" target="gba1 variant">
  <data key="d3">represents positive rate of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="neuronopathic gd" target="ataxia">
  <data key="d3">is a manifestation of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="alleles" target="mutant enzyme">
  <data key="d3">is related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="at-risk individuals" target="gba1-related parkinson's disease">
  <data key="d3">are at risk of or have developed</data>
  <data key="d4">1.0</data>
</edge>
<edge source="awareness" target="sidransky syndrome">
  <data key="d3">is necessary for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="awareness" target="neurologists">
  <data key="d3">lack</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical development" target="early stage">
  <data key="d3">is at</data>
  <data key="d4">1.0</data>
</edge>
<edge source="clinical development" target="novel pharmacological agents">
  <data key="d3">is in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="daily dose" target="milligrams (mg)">
  <data key="d3">measured in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="delivery" target="enzyme">
  <data key="d3">improves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="drug library" target="commercially approved drugs">
  <data key="d3">contains</data>
  <data key="d4">1.0</data>
</edge>
<edge source="early intervention" target="prodromal stage">
  <data key="d3">is applicable at</data>
  <data key="d4">1.0</data>
</edge>
<edge source="endogenous mutant enzyme" target="protein misfolding">
  <data key="d3">is a cause of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="exogenous wildtype enzyme" target="protein misfolding">
  <data key="d3">cannot correct</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gain of function mutation" target="gba1-related parkinson's disease">
  <data key="d3">is reason for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gain of function mutation" target="therapeutic strategies">
  <data key="d3">influences</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1 carriers" target="gba1-parkinson's disease (gba1-pd)">
  <data key="d3">are associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1 carriers" target="healthy volunteers">
  <data key="d3">are a subset of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1 d409v knock-out mouse model" target="gba1-related parkinson's disease">
  <data key="d3">is used to study</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1 gene" target="mutation">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1 gene" target="sidransky syndrome">
  <data key="d3">is associated with pathogenic variants in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1 gene" target="biallelic loss-of-function mutations">
  <data key="d3">is affected by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1 gene" target="gba1-related parkinson's disease">
  <data key="d3">is related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1 mutation" target="genetic mutations">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1 variant" target="odds ratio">
  <data key="d3">has an odds ratio of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1 variant" target="ropad study">
  <data key="d3">shows prevalence of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1-related parkinson's disease" target="reduction therapy">
  <data key="d3">is treated by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1-related parkinson's disease" target="pharmacological chaperones">
  <data key="d3">are used to treat</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1-related parkinson's disease" target="earlier age of onset">
  <data key="d3">has feature of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1-related parkinson's disease" target="established textbook knowledge">
  <data key="d3">is now established as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1-related parkinson's disease" target="genetic testing">
  <data key="d3">is relevant for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1-related parkinson's disease" target="higher likelihood of developing dementia">
  <data key="d3">has feature of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1-related parkinson's disease" target="more severe clinical course">
  <data key="d3">has feature of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1-related parkinson's disease" target="prodromal stages of parkinson's disease">
  <data key="d3">can precede</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1-related parkinson's disease" target="symptoms of parkinson's disease">
  <data key="d3">may present with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1-related parkinson's disease" target="treatment of parkinson's disease">
  <data key="d3">requires</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1-related parkinson's disease" target="venglustat">
  <data key="d3">related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1-related parkinson's disease" target="genetic etiology of parkinson's disease">
  <data key="d3">is the most common</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1-related parkinson's disease" target="rare diseases">
  <data key="d3">falls within the category of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1-related parkinson's disease" target="post-mortem brain analysis">
  <data key="d3">is evaluated in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1-related parkinson's disease" target="cns_complications">
  <data key="d3">is related to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gba1-related parkinson's disease" target="metabolic_aspects_of_gaucher_disease">
  <data key="d3">is not a manifestation of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="genetic mutations" target="protein folding defects">
  <data key="d3">can lead to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="genetic mutations" target="protein stability issues">
  <data key="d3">can lead to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="genetic mutations" target="genetic variants">
  <data key="d3">are types of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="genetic testing" target="lectures">
  <data key="d3">is not mentioned in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="genetic testing" target="neurologists">
  <data key="d3">awareness among</data>
  <data key="d4">1.0</data>
</edge>
<edge source="genetic testing" target="parkinson's disease population">
  <data key="d3">facilitates for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="genetic testing" target="movement disorders society">
  <data key="d3">does not include in discussions</data>
  <data key="d4">1.0</data>
</edge>
<edge source="genetic testing" target="movement disorders specialists">
  <data key="d3">need to perform</data>
  <data key="d4">1.0</data>
</edge>
<edge source="genetic testing" target="sidransky syndrome">
  <data key="d3">promotes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="glucocerebroside_substrate" target="lysosomal_compartments">
  <data key="d3">located in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="homeostasis" target="stress response mechanism">
  <data key="d3">aims to achieve</data>
  <data key="d4">1.0</data>
</edge>
<edge source="hypokinetic movement disorder" target="severity level">
  <data key="d3">is typically more severe with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="hypokinetic movement disorder" target="survival duration">
  <data key="d3">is shorter in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="increased awareness" target="sidransky syndrome">
  <data key="d3">promotes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="low awareness" target="rare diseases">
  <data key="d3">is characteristic of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="low-intensity focused ultrasound (lifu)" target="magnetic resonance imaging (mri)">
  <data key="d3">is used in conjunction with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="macrophage_cells" target="lysosomal_compartments">
  <data key="d3">contain</data>
  <data key="d4">1.0</data>
</edge>
<edge source="management of early parkinson’s disease" target="lectures">
  <data key="d3">is the title of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="medical community" target="neurologists">
  <data key="d3">lack of awareness in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="medical understanding" target="sidransky syndrome">
  <data key="d3">improves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="misfolded proteins" target="protein folding defects">
  <data key="d3">are associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="misfolded proteins" target="protein stability issues">
  <data key="d3">are associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="movement disorders society" target="international congress">
  <data key="d3">hosts</data>
  <data key="d4">1.0</data>
</edge>
<edge source="odds ratio" target="5.43">
  <data key="d3">is quantified as</data>
  <data key="d4">1.0</data>
</edge>
<edge source="parkinson's disease population" target="best interest">
  <data key="d3">serves the</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmacological chaperones (pcs)" target="disease modification">
  <data key="d3">highlight promising avenues for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmacological compound (pc)" target="ncgc326">
  <data key="d3">is an improved derivative of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="prodromal stages of parkinson's disease" target="diagnosis of parkinson's disease">
  <data key="d3">are important for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="protein misfolding" target="downstream effects">
  <data key="d3">stops</data>
  <data key="d4">1.0</data>
</edge>
<edge source="protein misfolding" target="proteins">
  <data key="d3">can occur in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="protein misfolding" target="wild-type glucocerebrosidase">
  <data key="d3">can occur in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="protein misfolding" target="quantitative assays">
  <data key="d3">identify</data>
  <data key="d4">1.0</data>
</edge>
<edge source="rare disease classification" target="200,000 cases">
  <data key="d3">is defined as less than</data>
  <data key="d4">1.0</data>
</edge>
<edge source="rare disease classification" target="united states">
  <data key="d3">has cases of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="recombinant glucocerebrosidase" target="central nervous system delivery">
  <data key="d3">is attempted for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="reduction therapy" target="phase i clinical trials">
  <data key="d3">is tested in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="reduction therapy" target="phase ii clinical trials">
  <data key="d3">is tested in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="safety trial" target="australia">
  <data key="d3">conducted in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="sanofi" target="venglustat">
  <data key="d3">invested in,stopped trial of</data>
  <data key="d4">2.0</data>
</edge>
<edge source="scientific understanding" target="sidransky syndrome">
  <data key="d3">improves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="sidransky syndrome" target="care transformation">
  <data key="d3">has potential to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="sidransky syndrome" target="dementia prevalence">
  <data key="d3">has higher</data>
  <data key="d4">1.0</data>
</edge>
<edge source="sidransky syndrome" target="diagnostic strategies">
  <data key="d3">advocates for increased awareness of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="sidransky syndrome" target="disease onset">
  <data key="d3">exhibits earlier</data>
  <data key="d4">1.0</data>
</edge>
<edge source="sidransky syndrome" target="disease severity">
  <data key="d3">exhibits more severe</data>
  <data key="d4">1.0</data>
</edge>
<edge source="sidransky syndrome" target="targeted therapies">
  <data key="d3">are emerging for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="sidransky syndrome" target="targeted treatments">
  <data key="d3">refines for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="stress response mechanism" target="unfolded protein response">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="therapeutic strategies" target="academic discourse">
  <data key="d3">is influenced by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="time to market" target="drug development process">
  <data key="d3">is shortened by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="total population" target="united states">
  <data key="d3">is part of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="toxicology assessment" target="drug development process">
  <data key="d3">is a stage in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="venglustat" target="placebo">
  <data key="d3">compared to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="venglustat" target="substrate">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="venglustat" target="therapeutic potential">
  <data key="d3">has great</data>
  <data key="d4">1.0</data>
</edge>
<edge source="venglustat_treatment" target="placebo_control">
  <data key="d3">compared to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="bioactive compounds" target="compound libraries">
  <data key="d3">are enriched with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="biological modulators" target="cellular regulation">
  <data key="d3">are involved in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="biological modulators" target="gsk-3 inhibitors">
  <data key="d3">are types of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="biological modulators" target="proteasome inhibitors">
  <data key="d3">are types of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cell-based assays" target="high-throughput screening">
  <data key="d3">are amenable to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cell-based assays" target="high-throughput screening (hts)">
  <data key="d3">is amenable to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cell-based assays" target="high-throughput assays">
  <data key="d3">are a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="cell-based assays" target="small-molecule gcase enhancers">
  <data key="d3">is a challenge for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="combinatorial matrix screening" target="synergistic interactions">
  <data key="d3">is a method to identify</data>
  <data key="d4">1.0</data>
</edge>
<edge source="compound identification" target="pharmacological validation">
  <data key="d3">is followed by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="compound identification" target="high-throughput screening (hts)">
  <data key="d3">drives</data>
  <data key="d4">1.0</data>
</edge>
<edge source="compound ncgc326" target="glucosylsphingosine accumulation">
  <data key="d3">reverses</data>
  <data key="d4">1.0</data>
</edge>
<edge source="compound ncgc326" target="proteostasis regulators">
  <data key="d3">enhances levels of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="compound ncgc326" target="lysosomal translocation">
  <data key="d3">is associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="final hit compounds" target="epigenetic mechanisms">
  <data key="d3">includes</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease cell model" target="lead discovery">
  <data key="d3">is amenable to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gaucher disease cell model" target="gba1-knockout h4 cells">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase enhancers" target="novel chemical entities">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase enhancers" target="physiologically relevant">
  <data key="d3">is a characteristic of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase-l444p variant" target="enzyme levels">
  <data key="d3">enhanced by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase-l444p variant" target="synergistic interactions">
  <data key="d3">involves</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gcase-l444p variant" target="pathogenic variant">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gsk-3 inhibitors" target="therapeutic applications">
  <data key="d3">are used in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="gsk-3 inhibitors" target="pladienolide b">
  <data key="d3">is a specific example of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="hibit peptide reporter tag" target="gcase variants">
  <data key="d3">preserves trafficking and function of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="hibit-gcase-l444p assay" target="lead discovery">
  <data key="d3">utility for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="hibit-gcase-l444p assay" target="protein complexes (pcs)">
  <data key="d3">detects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="hibit-gcase-l444p assay" target="protein residues (prs)">
  <data key="d3">detects</data>
  <data key="d4">1.0</data>
</edge>
<edge source="hibit-tagged gcase" target="endogenous gcase">
  <data key="d3">is comparable to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="hibit-tagged gcase" target="lysosomal localization">
  <data key="d3">shows</data>
  <data key="d4">1.0</data>
</edge>
<edge source="hibit-tagged gcase" target="moderate expression">
  <data key="d3">results in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="lysosomal activity" target="lysosomal translocation">
  <data key="d3">is associated with</data>
  <data key="d4">1.0</data>
</edge>
<edge source="molecular identification" target="pharmacological validation">
  <data key="d3">leads to</data>
  <data key="d4">1.0</data>
</edge>
<edge source="molecular identification" target="physiologically relevant assays">
  <data key="d3">facilitates</data>
  <data key="d4">1.0</data>
</edge>
<edge source="ncgc326" target="noninhibitory chaperones">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="panobinostat" target="proteostasis regulators">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pharmacological validation" target="medicinal chemistry optimization">
  <data key="d3">supports,is part of</data>
  <data key="d4">2.0</data>
</edge>
<edge source="pladienolide b" target="potent compounds">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="pladienolide b" target="proteostasis regulators">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="potent compounds" target="screening methods">
  <data key="d3">are identified by</data>
  <data key="d4">1.0</data>
</edge>
<edge source="potent compounds" target="trans-isrib">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="proteasome inhibitors" target="therapeutic applications">
  <data key="d3">are used in</data>
  <data key="d4">1.0</data>
</edge>
<edge source="proteasome inhibitors" target="trans-isrib">
  <data key="d3">is a specific example of</data>
  <data key="d4">1.0</data>
</edge>
<edge source="titration-based quantitative high-throughput screening" target="lead discovery">
  <data key="d3">is a method for</data>
  <data key="d4">1.0</data>
</edge>
<edge source="trans-isrib" target="proteostasis regulators">
  <data key="d3">is a type of</data>
  <data key="d4">1.0</data>
</edge>
</graph></graphml>